0001628280-23-027013.txt : 20230803 0001628280-23-027013.hdr.sgml : 20230803 20230803074408 ACCESSION NUMBER: 0001628280-23-027013 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230803 DATE AS OF CHANGE: 20230803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 231138112 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 10-Q 1 itci-20230630.htm 10-Q itci-20230630
000156751412-312023Q2false8625600015675142023-01-012023-06-3000015675142023-08-01xbrli:shares00015675142023-06-30iso4217:USD00015675142022-12-31iso4217:USDxbrli:shares0001567514us-gaap:ProductMember2023-04-012023-06-300001567514us-gaap:ProductMember2022-04-012022-06-300001567514us-gaap:ProductMember2023-01-012023-06-300001567514us-gaap:ProductMember2022-01-012022-06-300001567514us-gaap:GrantMember2023-04-012023-06-300001567514us-gaap:GrantMember2022-04-012022-06-300001567514us-gaap:GrantMember2023-01-012023-06-300001567514us-gaap:GrantMember2022-01-012022-06-3000015675142023-04-012023-06-3000015675142022-04-012022-06-3000015675142022-01-012022-06-300001567514us-gaap:CommonStockMember2021-12-310001567514us-gaap:AdditionalPaidInCapitalMember2021-12-310001567514us-gaap:RetainedEarningsMember2021-12-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100015675142021-12-310001567514us-gaap:CommonStockMember2022-01-012022-03-310001567514us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100015675142022-01-012022-03-310001567514us-gaap:RetainedEarningsMember2022-01-012022-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001567514us-gaap:CommonStockMember2022-03-310001567514us-gaap:AdditionalPaidInCapitalMember2022-03-310001567514us-gaap:RetainedEarningsMember2022-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100015675142022-03-310001567514us-gaap:CommonStockMember2022-04-012022-06-300001567514us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001567514us-gaap:RetainedEarningsMember2022-04-012022-06-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001567514us-gaap:CommonStockMember2022-06-300001567514us-gaap:AdditionalPaidInCapitalMember2022-06-300001567514us-gaap:RetainedEarningsMember2022-06-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000015675142022-06-300001567514us-gaap:CommonStockMember2022-12-310001567514us-gaap:AdditionalPaidInCapitalMember2022-12-310001567514us-gaap:RetainedEarningsMember2022-12-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001567514us-gaap:CommonStockMember2023-01-012023-03-310001567514us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100015675142023-01-012023-03-310001567514us-gaap:RetainedEarningsMember2023-01-012023-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001567514us-gaap:CommonStockMember2023-03-310001567514us-gaap:AdditionalPaidInCapitalMember2023-03-310001567514us-gaap:RetainedEarningsMember2023-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100015675142023-03-310001567514us-gaap:CommonStockMember2023-04-012023-06-300001567514us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001567514us-gaap:RetainedEarningsMember2023-04-012023-06-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001567514us-gaap:CommonStockMember2023-06-300001567514us-gaap:AdditionalPaidInCapitalMember2023-06-300001567514us-gaap:RetainedEarningsMember2023-06-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-30itci:Segment0001567514us-gaap:CustomerConcentrationRiskMemberitci:ThreeMajorWholesalersMemberus-gaap:SalesRevenueNetMember2023-01-012023-06-30xbrli:pure0001567514itci:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-06-300001567514itci:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-06-300001567514itci:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-06-300001567514us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-06-300001567514itci:FDICCertificatesOfDepositMember2023-06-300001567514us-gaap:CertificatesOfDepositMember2023-06-300001567514us-gaap:CommercialPaperMember2023-06-300001567514us-gaap:CorporateDebtSecuritiesMember2023-06-300001567514us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001567514itci:FDICCertificatesOfDepositMember2022-12-310001567514us-gaap:CertificatesOfDepositMember2022-12-310001567514us-gaap:CommercialPaperMember2022-12-310001567514us-gaap:CorporateDebtSecuritiesMember2022-12-310001567514us-gaap:FairValueInputsLevel3Member2022-12-310001567514us-gaap:FairValueInputsLevel3Member2023-06-300001567514us-gaap:CashAndCashEquivalentsMember2023-06-300001567514us-gaap:CashAndCashEquivalentsMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-06-300001567514us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-06-300001567514us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMember2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberitci:FDICCertificatesOfDepositMember2023-06-300001567514us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMember2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Member2023-06-300001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-06-300001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2023-06-300001567514us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2023-06-300001567514us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMember2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-06-300001567514us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-12-310001567514us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001567514us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberitci:FDICCertificatesOfDepositMember2022-12-310001567514us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Member2022-12-310001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2022-12-310001567514us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2022-12-310001567514us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001567514us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001567514stpr:NY2018-09-300001567514us-gaap:VehiclesMember2023-06-300001567514us-gaap:ProductMemberitci:BristolMyersSquibbCompanyMember2005-05-312023-06-300001567514us-gaap:ProductMemberitci:BristolMyersSquibbCompanyMember2023-06-300001567514us-gaap:ProductMemberitci:BristolMyersSquibbCompanyMember2005-05-310001567514us-gaap:ProductMemberitci:BristolMyersSquibbCompanyMembersrt:MinimumMember2005-05-312005-05-310001567514srt:MaximumMemberus-gaap:ProductMemberitci:BristolMyersSquibbCompanyMember2005-05-312005-05-310001567514us-gaap:ProductMemberitci:BristolMyersSquibbCompanyMember2023-01-012023-06-300001567514us-gaap:PurchaseCommitmentMember2023-06-300001567514us-gaap:PurchaseCommitmentMember2022-12-310001567514itci:InventoriableCostsMember2023-01-012023-06-300001567514itci:InventoriableCostsMember2022-01-012022-06-300001567514us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-06-300001567514us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-06-300001567514us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001567514us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-3000015675142022-01-012022-12-310001567514us-gaap:RestrictedStockUnitsRSUMember2022-12-310001567514us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001567514us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001567514us-gaap:RestrictedStockUnitsRSUMember2023-06-300001567514itci:TimeBasedRestrictedStockUnitsRSUMember2023-06-300001567514us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001567514us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001567514us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001567514us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001567514us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300001567514us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001567514us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300001567514us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001567514itci:MichaelIHalsteadMember2023-01-012023-06-300001567514itci:MichaelIHalsteadMember2023-04-012023-06-300001567514itci:MichaelIHalsteadMember2023-06-300001567514itci:SharonMatesMember2023-01-012023-06-300001567514itci:SharonMatesMember2023-04-012023-06-300001567514itci:SharonMatesMember2023-06-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 10-Q
_______________________
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023
or
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from_________to_________
Commission File Number: 001-36274
_______________________
INTRA-CELLULAR THERAPIES, INC.
(Exact name of registrant as specified in its charter)
_______________________
Delaware36-4742850
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
 
430 East 29th Street
New York, New York
10016
(Address of principal executive offices)(Zip Code)
(646) 440-9333
(Registrant’s telephone number, including area code)
_______________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common StockITCI
The Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filero
 
Non-accelerated fileroSmaller reporting companyo
 
  Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of August 1, 2023, the registrant had 96,091,564 shares of common stock outstanding.

Intra-Cellular Therapies, Inc.
Index to Form 10-Q
In this Quarterly Report on Form 10-Q, the terms “we,” “us,” “our,” and the “Company” mean Intra-Cellular Therapies, Inc. and our subsidiary. “ITI” refers to our wholly-owned subsidiary ITI, Inc.
i
PART I: FINANCIAL INFORMATION
Item 1.    FINANCIAL STATEMENTS
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Balance Sheets (in thousands except share and per share amounts)
June 30,
2023		December 31,
2022
(Unaudited)
Assets
Current assets:
Cash and cash equivalents$142,258 $148,615 
Investment securities, available-for-sale370,596 443,290 
Restricted cash1,750 1,750 
Accounts receivable, net95,964 75,189 
Inventory41,895 23,920 
Prepaid expenses and other current assets45,610 45,193 
Total current assets698,073 737,957 
Property and equipment, net1,656 1,913 
Right of use assets, net13,787 14,824 
Other assets86 86 
Total assets$713,602 $754,780 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$7,733 $10,395 
Accrued and other current liabilities27,456 19,657 
Accrued customer programs31,710 25,621 
Accrued employee benefits21,623 22,996 
Operating lease liabilities3,558 4,567 
Total current liabilities92,080 83,236 
Operating lease liabilities, non-current14,432 15,474 
Total liabilities106,512 98,710 
Stockholders’ equity:
Common stock, $0.0001 par value: 175,000,000 shares authorized at June 30, 2023 and December 31, 2022; 96,083,387 and 94,829,794 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively
10 9 
Additional paid-in capital2,173,671 2,137,737 
Accumulated deficit(1,564,323)(1,477,486)
Accumulated comprehensive loss(2,268)(4,190)
Total stockholders’ equity607,090 656,070 
Total liabilities and stockholders’ equity$713,602 $754,780 
See accompanying notes to these condensed consolidated financial statements.
1
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Operations (in thousands except share and per share amounts) (Unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Revenues
Product sales, net$110,128 $55,074 $204,859 $89,829 
Grant revenue664 505 1,239 746 
Total revenues, net110,792 55,579 206,098 90,575 
Operating expenses:
Cost of product sales7,163 4,650 13,914 7,805 
Selling, general and administrative101,014 100,316 199,937 175,776 
Research and development49,794 38,536 87,818 67,579 
Total operating expenses157,971 143,502 301,669 251,160 
Loss from operations(47,179)(87,923)(95,571)(160,585)
Interest income4,530 1,320 8,879 1,868 
Loss before provision for income taxes(42,649)(86,603)(86,692)(158,717)
Income tax expense(135)— (145)(5)
Net loss$(42,784)$(86,603)$(86,837)$(158,722)
Net loss per common share:
Basic & Diluted$(0.45)$(0.92)$(0.91)$(1.70)
Weighted average number of common shares:
Basic & Diluted95,948,06394,285,11795,543,62693,449,424
See accompanying notes to these condensed consolidated financial statements.
2
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Comprehensive Loss (in thousands) (Unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Net loss$(42,784)$(86,603)$(86,837)$(158,722)
Other comprehensive gain (loss):
Unrealized gain (loss) on investment securities430 (1,474)1,922 (4,438)
Comprehensive loss$(42,354)$(88,077)$(84,915)$(163,160)
See accompanying notes to these condensed consolidated financial statements.
3
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Stockholders’ Equity (in thousands except share and per share amounts) (Unaudited)
Common StockAdditional
Paid-in
Capital		Accumulated
Deficit		Accumulated
Comprehensive
(Loss) Income		Total
Stockholders’
Equity
SharesAmount
Balance at December 31, 202181,886,965$8 $1,639,476 $(1,221,230)$(364)$417,890 
Common shares issued January 7, 202210,952,3811 433,724 — — 433,725 
Exercise of stock options and issuances of restricted stock1,180,696— 8,089 — — 8,089 
Stock issued for services383— 24 — — 24 
Share-based compensation—— 8,105 — — 8,105 
Net loss—— — (72,119)— (72,119)
Other comprehensive loss—— — — (2,964)(2,964)
Balance at March 31, 202294,020,425$9 $2,089,418 $(1,293,349)$(3,328)$792,750 
Exercise of stock options and issuances of restricted stock346,411— 5,504 — — 5,504 
Stock issued for services397— 22 — — 22 
Share-based compensation—— 11,998 — — 11,998 
Net loss—— — (86,603)— (86,603)
Other comprehensive loss—— — — (1,474)(1,474)
Balance at June 30, 202294,367,233$9 $2,106,942 $(1,379,952)$(4,802)$722,197 

Balance at December 31, 202294,829,794$9 $2,137,737 $(1,477,486)$(4,190)$656,070 
Exercise of stock options and issuances of restricted stock849,8271 3,639 — — 3,640 
Stock issued for services408— 22 — — 22 
Share-based compensation—— 10,439 — — 10,439 
Net loss—— — (44,053)— (44,053)
Other comprehensive gain—— — — 1,492 1,492 
Balance at March 31, 202395,680,029$10 $2,151,837 $(1,521,539)$(2,698)$627,610 
Exercise of stock options and issuances of restricted stock402,994— 8,585 — — 8,585 
Stock issued for services364— 23 — — 23 
Share-based compensation—— 13,226 — — 13,226 
Net loss—— — (42,784)— (42,784)
Other comprehensive gain—— — — 430 430 
Balance at June 30, 202396,083,387$10 $2,173,671 $(1,564,323)$(2,268)$607,090 
See accompanying notes to these condensed consolidated financial statements.
4
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited)
Six Months Ended June 30,
20232022
Cash flows used in operating activities
Net loss$(86,837)$(158,722)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation257 343 
Share-based compensation23,665 20,103 
Stock issued for services45 46 
Amortization of premiums and accretion of discounts on investment securities, net(3,670)(947)
Changes in operating assets and liabilities:
Accounts receivable, net(20,775)(26,820)
Inventory(17,975)(17,074)
Prepaid expenses and other assets(417)(12,535)
Accounts payable(2,662)2,058 
Accrued and other current liabilities7,799 6,201 
Accrued customer programs6,089 10,519 
Accrued employee benefits(1,373)(2,512)
Operating lease liabilities, net(1,014)1,698 
Net cash used in operating activities(96,868)(177,642)
Cash flows provided by (used in) investing activities
Purchases of investments(174,411)(552,782)
Maturities of investments252,697 268,665 
Purchases of property and equipment— (689)
Net cash provided by (used in) investing activities78,286 (284,806)
Cash flows provided by financing activities
Proceeds of public offering, net— 433,725 
Proceeds from exercise of stock options12,225 13,593 
Net cash provided by financing activities12,225 447,318 
Net decrease in cash, cash equivalents, and restricted cash(6,357)(15,130)
Cash, cash equivalents, and restricted cash at beginning of period150,365 93,765 
Cash, cash equivalents, and restricted cash at end of period$144,008 $78,635 
Non-cash investing and financing activities
Right of use assets under operating leases$— $4,167 
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:
June 30,
20232022
Cash and cash equivalents$142,258 $77,235 
Restricted cash1,7501,400
Total cash, cash equivalents and restricted cash$144,008 $78,635 
See accompanying notes to these condensed consolidated financial statements.
5
Intra-Cellular Therapies, Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)
June 30, 2023
1. Organization
Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiary, ITI, Inc. (“ITI”), is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (“CNS”). In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42mg/day) and the Company initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42mg/day). The Company initiated the commercial launch of CAPLYTA for the treatment of bipolar depression in December 2021. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). The commercial launch of these special population doses occurred in August 2022. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression. Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder.
In order to further its commercial activities and research projects and support its collaborations, the Company may require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt or convertible debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s products, product candidates and technology and, to a much lesser extent, grant funding.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders.
Recent Accounting Pronouncements
Management has evaluated all accounting pronouncements issued through the date of the condensed consolidated financial statements and does not believe that any recently issued, but not yet effective, pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.
6
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Significant Accounting Policies
The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. As of June 30, 2023, the majority of the Company’s accounts receivable, net arose from product sales in the United States. For the six-month period ended June 30, 2023, 96% of sales were from three major wholesalers accounting for approximately 37%, 30%, and 29% of product sales. The percentage of the total net product sales by individual customers has not significantly changed since inception. All customers have standard payment terms which generally require payment within 60 days. As of June 30, 2023, the Company continues to believe that such customers are of high credit quality.
3. Investment Securities
Investment securities consisted of the following (in thousands):
June 30, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$219,575 $3 $(1,203)$218,375 
FDIC Certificates of Deposit5,132 — (58)5,074 
Certificates of Deposit65,000 — — 65,000 
Commercial Paper74,541 — (207)74,334 
Corporate Notes/Bonds88,553 1 (804)87,750 
$452,801 $4 $(2,272)$450,533 
December 31, 2022
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$188,465 $14 $(1,729)$186,750 
FDIC Certificates of Deposit4,155 3 (72)4,086 
Certificates of Deposit7,500 — — 7,500 
Commercial Paper100,711 3 (269)100,445 
Corporate Notes/Bonds189,588 1 (2,141)187,448 
$490,419 $21 $(4,211)$486,229 
The Company has classified all of its investment securities as available-for-sale, including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of June 30, 2023 and December 31, 2022, the Company held $25.5 million and $71.5 million, respectively, of available-for-sale investment securities with contractual maturity dates more than one year and less than two years, with the remainder of the available-for-sale investment securities having contractual maturity dates less than one year.
7
Unrealized losses as of June 30, 2023 approximate 1% of the estimated fair value of investments. The aggregate related fair value of investments with unrealized losses as of June 30, 2023 was $355.4 million, which consisted of $194.5 million from U.S. government agency securities, $5.1 million of certificates of deposit, $74.3 million of commercial paper, and $81.5 million of corporate notes/bonds. $83.8 million of the aggregate fair value of investments with unrealized losses as of June 30, 2023 has been held in a continuous unrealized loss position for over 12 months, with the remaining $271.6 million held in a continuous unrealized loss position for less than 12 months. As of December 31, 2022, the aggregate related fair value of investments with unrealized losses was $438.3 million. $49.1 million of the aggregate fair value of investments with unrealized losses as of December 31, 2022 had been held in a continuous unrealized loss position for over than 12 months, with the remaining $389.2 million held in a continuous unrealized loss position for less than 12 months.
The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.
4. Fair Value Measurements
The Company applies the fair value method under ASC Topic 820, Fair Value Measurements and Disclosures. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:
•Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
•Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
•Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.
The Company has no assets or liabilities that were measured using prices with significant unobservable inputs (Level 3 assets and liabilities) as of June 30, 2023 and December 31, 2022. The carrying value of cash held in money market funds of $5.3 million as of June 30, 2023 and $12.2 million as of December 31, 2022 is included in cash and cash equivalents on the condensed consolidated balance sheets and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in commercial paper of $5.0 million, U.S. government agency securities of $10.0 million and certificates of deposit of $65.0 million as of June 30, 2023 is included in cash and cash equivalents. The carrying value of cash held in commercial paper of $14.9 million, U.S. government agency securities of $20.5 million and certificates of deposit of $7.5 million as of December 31, 2022 is included in cash and cash equivalents.
8
The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):
Fair Value Measurements at
Reporting Date Using
June 30,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$5,319 $5,319 $— $— 
U.S. Government Agency Securities218,375 — 218,375 — 
FDIC Certificates of Deposit5,074 — 5,074 — 
Certificates of Deposit65,000 — 65,000 — 
Commercial Paper74,334 — 74,334 — 
Corporate Notes/Bonds87,750 — 87,750 — 
$455,852 $5,319 $450,533 $— 
Fair Value Measurements at
Reporting Date Using
December 31,
2022		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$12,203 $12,203 $— $— 
U.S. Government Agency Securities186,750 — 186,750 — 
FDIC Certificates of Deposit4,086 — 4,086 — 
Certificates of Deposit7,500 — 7,500 — 
Commercial Paper100,445 — 100,445 — 
Corporate Notes/Bonds187,448 — 187,448 — 
$498,432 $12,203 $486,229 $— 
5. Inventory
Inventory consists of the following (in thousands):
June 30,
2023		December 31,
2022
Raw materials$33,901 $17,227 
Work in process4,051 2,594 
Finished goods3,943 4,099 
$41,895 $23,920 
The raw materials balance includes the active pharmaceutical ingredients (API) and any related intermediate compounds, which, supply exceeds 12 months of production needs.
9
6. Right of Use Assets and Lease Liabilities
In 2014, the Company entered into a long-term lease with a related party, which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium-related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029.
The Company has also entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to obtain motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The contractual period of each lease is 12 months, followed by month-to-month renewal periods. The Company estimates the lease term for each vehicle to be 12 months. Leases which the Company determined to have a lease term of 12 months or less will be treated as short-term in accordance with the accounting policy election and are not recognized on the balance sheet. Each lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.75 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease, which has been recorded as restricted cash on the condensed consolidated balance sheets.
The Company has no other significant leases. In addition, no identified leases require allocations between lease and non-lease components.
The following tables present the lease balances within the condensed consolidated balance sheets, weighted average remaining lease term, and the weighted average discount rates related to leases as of June 30, 2023 and December 31, 2022 and operating cash outflows as of June 30, 2023 and 2022 (in thousands, except years and percentages):
June 30, 2023December 31, 2022
Other information
Weighted average remaining lease term5.8 years5.9 years
Weighted average discount rate9.07 %8.76 %
Six Months Ended June 30,
20232022
Lease cost
Operating lease cost$2,003$2,843
Variable lease cost724806
Short-term lease cost599—
$3,326$3,649
10
Maturity analyses under the lease agreements are as follows (in thousands):
Six months ending December 31, 2023$1,848 
Year ending December 31, 20243,792 
Year ending December 31, 20253,907 
Year ending December 31, 20263,974 
Year ending December 31, 20274,022 
Thereafter5,915 
Total23,458 
Less: Present value discount(5,468)
Total operating lease liability17,990 
Less: Current portion(3,558)
Operating lease liabilities, non-current$14,432 
7. Commitments and Contingencies
License and Royalty Commitments
On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and know-how of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds.
Under the agreement, the Company has made payments of $10.75 million to BMS related to milestones achieved to date for lumateperone. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of non-royalty payments made in consideration of any sublicense.
The agreement extends, and royalties are payable, on a country-by-country and product-by-product basis, through the later of ten years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.
Purchase Commitments
The Company enters into certain other long-term commitments for goods and services that are outstanding for periods greater than one year. The Company recently amended certain manufacturing service agreements committing the Company to certain minimum annual purchase commitments for which the Company anticipates making payments within the years 2025 through 2029. As of June 30, 2023, the Company has committed to purchasing production campaigns for various raw materials including active pharmaceutical ingredients (API) and its intermediates from each of its supply vendors. The current campaigns are expected to be received into inventory during 2023 and 2024. The Company has paid deposits of $19.4 million and $21.6 million as of June 30, 2023 and December 31, 2022, respectively, for the various campaigns, which are recorded within prepaid expenses and other current assets. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan within the executed agreements.
11
8. Share-Based Compensation
Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs) granted to employees and directors recognized during the six-month periods ended June 30, 2023 and 2022, was comprised of the following (in thousands):
Six Months Ended June 30,
20232022
Inventoriable costs$762 $824 
Selling, general and administrative15,705 12,224 
Research and development7,198 7,055 
Total share-based compensation expense$23,665 $20,103 
Information regarding the stock options activity, including with respect to grants to employees and directors as of June 30, 2023, and changes during the six-month period then ended, are summarized as follows:
Number of
Shares		Weighted-
Average
Exercise
Price		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20224,785,972$26.27 5.8 years
Options granted 2023275,420
Options exercised 2023(510,274)
Options canceled or expired 2023(35,930)
Outstanding at June 30, 20234,515,188$27.62 
Vested and expected to vest at June 30, 20234,515,188$27.62 
Exercisable at June 30, 20233,739,052$23.18 
The fair value of the time-based RSUs is based on the closing price of the Company’s common stock on the date of grant. Information regarding the time-based RSU activity and changes during the six-month period ended June 30, 2023 is summarized as follows:
Number of
Shares		Weighted-Average
Grant Date
Fair Value Per Share		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20221,274,664$42.76 0.8 years
Time-based RSUs granted in 20231,056,867
Time-based RSUs vested in 2023(655,204)
Time-based RSUs cancelled in 2023(50,056)
Outstanding at June 30, 20231,626,271$48.62 
As of June 30, 2023, there was approximately $68.5 million of unrecognized compensation costs estimated related to unvested time-based RSUs.
12
9. Loss Per Share
The following share-based awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and six-month periods ended June 30, 2023 and 2022:
Three and Six Months Ended
June 30,
20232022
Stock options4,515,1885,241,804
RSUs1,841,8551,517,820
13
Item 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto that appear elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K filed on March 1, 2023. In addition to historical information, the following discussion and analysis includes forward-looking information that involves risks, uncertainties and assumptions. Our actual results and the timing of events could differ materially from those anticipated by these forward-looking statements as a result of many factors, including those discussed under “Risk Factors” in our Annual Report on Form 10-K filed on March 1, 2023, as updated from time to time in our subsequent periodic and current reports filed with the SEC.
Overview
We are a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration, or FDA, for the treatment of schizophrenia in adults (42mg/day) and we initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42mg/day). We initiated the commercial launch of CAPLYTA for the treatment of bipolar depression in December 2021. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). We initiated the commercial launch of these special population doses in August 2022. As used in this report, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression.

Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder, or MDD. Patient enrollment in Study 501 and Study 502, global Phase 3 clinical trials evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD, is ongoing. In addition, we recently initiated a third global Phase 3 trial, Study 505, also evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD. Study 505 is intended to serve as a potential additional registration trial in support of a supplemental New Drug Application, or sNDA, for approval of lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD, if needed. This is a common strategy employed in mood disorder development programs. We expect to announce topline results from Study 501 in the first quarter of 2024 and Study 502 in the second quarter of 2024 and, subject to the results of these studies, we expect to file an sNDA with the FDA for approval of lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD in the second half of 2024. In the first quarter of 2020, as part of our lumateperone bipolar depression clinical program, we initiated our third monotherapy Phase 3 study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with bipolar I or bipolar II disorder. Following the positive results in our adjunctive study that was part of our bipolar depression clinical program, Study 402, we amended Study 403 to evaluate major depressive episodes with mixed features in bipolar disorder in patients with bipolar I or bipolar II disorder and mixed features in patients with MDD. In March 2023, we announced positive topline results from Study 403 as lumateperone 42mg given once daily met the primary endpoint in the study by demonstrating a statistically significant and clinically meaningful reduction in the Montgomery Asberg Depression Rating Scale (MADRS) total score compared to placebo at Week 6 in the combined patient population of MDD with mixed features and bipolar depression with mixed features (5.7 point reduction v. placebo; p<0.0001; Cohen’s d effect size (ES) of 0.64). Robust results were also seen in the individual patient population of MDD with mixed features (5.9 point reduction v. placebo; p<0.0001; ES= 0.67), and in the individual patient population of bipolar depression with mixed features (5.7 point reduction v. placebo; p<0.0001; ES= 0.64). Additionally, lumateperone 42mg met the key secondary endpoint in the study by demonstrating a statistically significant and clinically meaningful reduction in the clinician’s assessment of improvement in the overall severity on the Global Impression of Severity Scale (CGI-S) score compared to placebo at Week 6 in the combined patient population of MDD with mixed features and bipolar depression with mixed features (p<0.0001; ES= 0.59) and in the individual patient population of MDD with mixed features (p=0.0003; ES= 0.57), as well as the individual patient population of bipolar depression with mixed features p<0.0001; ES=0.61). We expect to discuss the results of Study 403 with the FDA in the second half of this year.
14
We have also initiated a Phase 3 study evaluating lumateperone for the prevention of relapse in patients with schizophrenia. The study is being conducted in five phases consisting of a screening phase; a 6-week, open-label run-in phase during which all patients will receive 42 mg of lumateperone per day; a 12-week, open-label stabilization phase during which all patients will receive 42 mg of lumateperone per day; a double-blind treatment phase, 26 weeks in duration, during which patients receive either 42 mg of lumateperone per day or placebo (1:1 ratio); and a 2-week safety follow-up phase. This study is being conducted in accordance with our post approval marketing commitment to the FDA in connection with the approval of CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics.
Within the lumateperone portfolio, we are also developing a long-acting injectable, or LAI, formulation to provide more treatment options to patients suffering from mental illness. We have completed the pre-clinical development of an LAI formulation, and we have conducted a Phase 1 single ascending dose study with this formulation. This study evaluated the pharmacokinetics, safety and tolerability of lumateperone LAI in patients with stable symptoms of schizophrenia. We completed this study, and it was safe and well-tolerated. We are evaluating several additional formulations of the lumateperone LAI with treatment durations of one month and longer. We expect to initiate Phase 1 single ascending dose studies with several formulations of our LAI later in 2023 and expect these studies to continue through 2024. Given the encouraging tolerability data to date with oral lumateperone, we believe that an LAI option, in particular, may lend itself to being an important formulation choice for certain patients.
We are developing ITI-1284-ODT-SL for the treatment of agitation in patients with dementia, the treatment of dementia-related psychosis and the treatment of certain depressive disorders in the elderly. ITI-1284-ODT-SL is a deuterated form of lumateperone, a new molecular entity formulated as an oral disintegrating tablet for sublingual administration. ITI-1284-ODT-SL is formulated as an oral solid dosage form that dissolves almost instantly when placed under the tongue, allowing for ease of use in the elderly and may be particularly beneficial for patients who have difficulty swallowing conventional tablets. Phase 1 single and multiple ascending dose studies in healthy volunteers and healthy elderly volunteers (> than 65 years of age) evaluated the safety, tolerability and pharmacokinetics of ITI-1284-ODT-SL. In these studies, there were no reported serious adverse events in either age group. In the elderly cohort, reported adverse events were infrequent with the most common adverse event being transient dry mouth (mild). Based on these results, we have initiated our program evaluating ITI-1284-ODT-SL for the treatment of agitation in patients with Alzheimer’s disease. We are in discussions with the FDA regarding the non-clinical toxicological profile of ITI-1284-ODT-SL. The FDA has informed us that they do not believe the deuterated and undeuterated forms of lumateperone are identical. As a result, the non-clinical data from lumateperone may not be broadly applied to ITI-1284-ODT-SL, and we are conducting additional toxicology studies. We expect to commence clinical conduct in a Phase 2 study in patients with generalized anxiety disorder in 2023. Additional studies in patients with psychosis in Alzheimer's disease and in patients with agitation in Alzheimer's disease are also planned for 2023. We are continuing with Phase 1 studies with ITI-1284-ODT-SL, including drug-drug interaction studies.
We have another major program that has yielded a portfolio of compounds that selectively inhibit the enzyme phosphodiesterase type 1, or PDE1. PDE1 enzymes are highly active in multiple disease states, and our PDE1 inhibitors are designed to reestablish normal function in these disease states. Abnormal PDE1 activity is associated with cellular proliferation and activation of inflammatory cells. Our PDE1 inhibitors ameliorate both of these effects in animal models. We intend to pursue the development of our phosphodiesterase, or PDE, program, for the treatment of aberrant immune system activation in several CNS and non-CNS conditions with a focus on diseases where excessive PDE1 activity has been demonstrated and increased inflammation is an important contributor to disease pathogenesis. Our potential disease targets include immune system regulation, neurodegenerative diseases, cancers and other non-CNS disorders. Lenrispodun (ITI-214) is our lead compound in this program. Following the favorable safety and tolerability results in our Phase 1 program, we initiated our development program for lenrispodun for Parkinson’s disease and conducted a Phase 1/2 clinical trial of lenrispodun in patients with Parkinson’s disease to evaluate safety and tolerability in this patient population, as well as motor and non-motor exploratory endpoints. In this study, lenrispodun was generally well-tolerated with a favorable safety profile and clinical signs consistent with improvements in motor symptoms and dyskinesias. Our Phase 2 clinical trial of lenrispodun evaluating improvements in motor symptoms, changes in cognition, and inflammatory biomarkers in patients with Parkinson’s disease is ongoing. We also have an active Investigational New Drug application to evaluate our newest candidate within the PDE 1 inhibitor program, ITI-1020, as a novel cancer immunotherapy. Our Phase 1 program with ITI-1020 in healthy volunteers is ongoing.
We also have a development program with our ITI-333 compound as a potential treatment for substance use disorders, pain and psychiatric comorbidities including depression and anxiety. There is a pressing need to develop new drugs to treat opioid addiction and safe, effective, non-addictive treatments to manage pain. ITI-333 is a novel compound that uniquely combines activity as an antagonist at serotonin 5-HT2A receptors and a partial agonist at µ-opioid receptors.
15
These combined actions support the potential utility of ITI-333 in the treatment of opioid use disorder and associated comorbidities (e.g., depression, anxiety, sleep disorders) without opioid-like safety and tolerability concerns. We have conducted a Phase 1 single ascending dose study evaluating the safety, tolerability and pharmacokinetics of ITI-333 in healthy volunteers. In this study, ITI-333 achieved plasma exposures at or above those required for efficacy and was generally safe and well-tolerated. We have commenced a neuroimaging study to investigate brain occupancy for receptors that play a role in substance use disorder and also have applicability for pain. The results of this study will support the dose selection for future studies. We also commenced a multiple ascending dose study with ITI-333 in the first quarter of 2023. We have received a grant from the National Institute on Drug Abuse under the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, that we expect will fund a significant portion of the early stage clinical development costs associated with this program.
We have assembled a management team with significant industry experience to lead the commercialization of our product and the discovery, development and potential commercialization of our product candidates. We complement our management team with a group of scientific and clinical advisors that includes recognized experts in the fields of schizophrenia, bipolar depression and other CNS disorders.
COVID-19
The COVID-19 pandemic has had widespread, rapidly evolving, and unpredictable impacts on global societies, economies, financial markets, and business practices. We continue to closely monitor the evolution and global impact of the COVID-19 pandemic, the identification of new variants of the COVID-19 virus and related developments, and our focus remains on promoting employee health and safety while continuing to advance the commercialization of our products and the research and development of our product candidates. Please refer to our Risk Factors in Part I, Item IA of our Annual Report on Form 10-K for further discussion of risks related to the COVID-19 pandemic.
Results of Operations
The following discussion summarizes the key factors our management believes are necessary for an understanding of our financial statements.
Revenues
Net revenues from product sales consist of sales of CAPLYTA, which was approved by the FDA for the treatment of schizophrenia in adults in December 2019 and for the treatment of bipolar depression in adults in December 2021. In addition, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA for certain patients. During the three and six-month period ended June 30, 2023, net product sales increased to approximately $110.1 million and $204.9 million, respectively, from approximately $55.1 million and $89.8 million for the three and six-month period ended June 30, 2022, respectively.
Expenses
The process of researching, developing and commercializing drugs for human use is lengthy, unpredictable and subject to many risks. The costs associated with the commercialization of CAPLYTA are substantial and will be incurred prior to our generating sufficient revenue to offset these costs. Costs for the clinical development of lumateperone-related projects, including for the treatment of MDD, consume and, together with our required post-marketing studies and other anticipated clinical development programs, will continue to consume a large portion of our current, as well as projected, resources. We intend to pursue other disease indications that lumateperone may address, but there are significant costs associated with pursuing FDA approval for those indications, which would include the cost of additional clinical trials.
Our PDE, ITI-1284 and ITI-333 development programs are currently in clinical development. Our other programs are still in the pre-clinical stages and will require extensive funding not only to complete pre-clinical testing, but also to commence and complete clinical trials. Expenditures that we incur in connection with these programs will be subject to availability of funding in addition to the funding required for the advancement of lumateperone. Any failure or delay in the advancement of lumateperone could require us to re-allocate resources from our other programs to the advancement of lumateperone, which could have a material adverse impact on the advancement of these other programs and on our results of operations.
16
Our operating expenses are comprised of (i) costs of product sales; (ii) selling expenses; (iii) general and administrative expenses; and (iv) research and development expenses.
Costs of product sales are comprised of:
•royalty payments on product sales;
•direct costs of formulating, manufacturing and packaging drug product; and
•overhead costs consisting of labor, share-based compensation, shipping, outside inventory manufacturing and other miscellaneous operating costs.
Selling expenses are incurred in three major categories:
•salaries and related benefit costs of a dedicated sales force;
•marketing and promotion expenses; and
•sales operation costs.
General and administrative expenses are incurred in three major categories:
•salaries and related benefit costs;
•patent, legal, and professional costs; and
•office and facilities overhead.
Research and development costs are comprised of:
•fees paid to external parties that provide us with contract services, such as pre-clinical testing, manufacturing and related testing, clinical trial activities and license milestone payments; and
•internal recurring costs, such as costs relating to labor and fringe benefits, materials, supplies, facilities and maintenance.

Product sold through June 30, 2023 consisted of active pharmaceutical ingredient (API) and drug product that was previously charged to research and development expenses prior to FDA approval of CAPLYTA and other direct, indirect, and overhead costs required to make final product for sale. Because the Company’s policy does not allow for the capitalization of pre-approval product, the cost of drug product sold is lower than it would have been and has a positive impact on our cost of product sales for the three and six-month periods ended June 30, 2023 and 2022. We expect to continue to have this favorable impact on cost of product sales and related product gross margins until the cost of our sales of CAPLYTA include drug product that is manufactured entirely after the FDA approval. We expect that this will be the case for the near-term and, as a result, our cost of product sales is less than we anticipate it will be in future periods. In addition, as our net product sales increase in the future and, we exceed certain sales thresholds, the applicable royalty rate for payments we make under our License Agreement with BMS will increase, which we anticipate will result in an increase to cost of product sales.
We expect that research and development expenses will increase moderately as we proceed with our clinical trials including, increased manufacturing of drug product for clinical trials and pre-clinical development activities. We also expect that our selling, general and administrative costs will increase from prior periods primarily due to costs associated with promotional activities to support the commercial sales of CAPLYTA as well as costs associated with building and maintaining infrastructure, which will include hiring additional personnel and increasing technological capabilities. We granted significant share-based awards in 2023 and 2022. We expect to continue to grant share-based awards in the future. We expect that our growing employee base will increase our share-based compensation expense in future periods. In addition, inflation generally may affect us by increasing clinical trial and other operational costs. To date, inflation has not had a material impact on our business, but if the global inflationary trends continue, we expect appreciable increases in clinical trial, selling, labor, and other operating costs.
17
The following table sets forth our revenues, operating expenses, interest income and income tax expense for the three and six-month periods ended June 30, 2023 and 2022 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
(Unaudited) (Unaudited)
Revenues
Product sales, net$110,128 $55,074 $204,859 $89,829 
Grant revenue664 505 1,239 746 
Total revenues110,792 55,579 206,098 90,575 
Expenses
Cost of product sales7,163 4,650 13,914 7,805 
Selling, general and administrative101,014 100,316 199,937 175,776 
Research and development49,794 38,536 87,818 67,579 
Total operating expenses157,971 143,502 301,669 251,160 
Loss from operations(47,179)(87,923)(95,571)(160,585)
Interest income4,530 1,320 8,879 1,868 
Income tax expense(135)— (145)(5)
Net loss$(42,784)$(86,603)$(86,837)$(158,722)
Comparison of Three and Six-Month Periods Ended June 30, 2023 and June 30, 2022
Product Sales, Net
Net product sales were $110.1 million and $204.9 million, respectively, for the three and six-month periods ended June 30, 2023, compared to $55.1 million and $89.8 million for the three and six-month periods ended June 30, 2022, respectively. Net product sales for the periods presented are comprised of sales of CAPLYTA for the treatment of schizophrenia and bipolar depression.
Cost of Product Sales
Cost of product sales was $7.2 million and $13.9 million, respectively, for the three and six-month periods ended June 30, 2023, respectively, compared to $4.7 million and $7.8 million for the three and six-month periods ended June 30, 2022, respectively. Cost of product sales consisted primarily of product royalty fees, direct and overhead costs. Drug product costs, including certain direct, indirect, and overhead costs, for product sales from commercial launch through June 30, 2023 were previously charged to research and development expenses prior to FDA approval in December 2019 and are not a component of cost of product sales. This minimal cost drug product had a favorable impact on our cost of product sales and related product gross margins for the three and six-month periods ended June 30, 2023 and 2022.
We will continue to have a lower cost of product sales that excludes the cost of the drug product that was incurred prior to FDA approval until our sales of CAPLYTA include drug product that is entirely manufactured after the FDA approval. We expect that this will be the case for the near-term and, as a result, our cost of product sales will be less than we anticipate it will be in future periods.
Selling, General and Administrative Expenses
Selling, general and administrative costs for the three-month period ended June 30, 2023 were $101.0 million as compared to $100.3 million in the three-month period ended June 30, 2022, which represents an increase of 1%.
Selling costs were $76.1 million for the three-month period ended June 30, 2023 as compared to selling costs of $81.3 million in the same period in 2022, which represents a decrease of 6%. This decrease is primarily due to a decrease of marketing and advertising expenses of $11.8 million and is partially offset by an increase in sales related labor costs of $5.0 million and $1.6 million of travel and other sales related expenses. Salaries, bonuses and related benefit costs for our sales and marketing functions for the three-month periods ended June 30, 2023 and 2022 constituted 38% and 29%, respectively, of our selling costs.
18
General and administrative expenses were $24.9 million in the three-month period ended June 30, 2023 as compared to $19.0 million for the same period in 2022, an increase of 31%. This increase is due to increases in share-based compensation of $2.2 million, insurance and other expenses of $1.7 million, labor related costs of $1.4 million, and information technology related costs of $0.6 million. Salaries, bonuses and related benefit costs for our general and administrative functions for the three-month periods ended June 30, 2023 and 2022 constituted 59% and 58%, respectively, of our general and administrative costs.
Selling, general and administrative costs for the six-month period ended June 30, 2023 were $199.9 million as compared to $175.8 million in the six-month period ended June 30, 2022, which represents an increase of 14%, which was due to an increase in selling, marketing, and advertising expenses and an increase in general and administrative expenses as discussed below.
Selling costs were $152.5 million for the six-month period ended June 30, 2023 as compared to $137.3 million in the same period in 2022, or an increase of 11%. This increase is primarily due to increases in commercialization costs of $7.5 million, sales related labor costs of approximately $6.1 million and approximately $1.6 million in travel and other sales related expenses. Salaries, bonuses and related benefit costs for our sales and marketing functions for the six-months ended June 30, 2023 and 2022 constituted approximately 35%, respectively, of our selling costs.
General and administrative expenses for the six-months ended June 30, 2023 were $47.4 million as compared to $38.4 million for the same period in 2022, an increase of 23%. This increase is due to increases in stock compensation expense of $3.5 million, labor related expense of $2.2 million, and the remainder for insurance, lease expense, and other administrative expenses. Salaries, bonuses and related benefit costs for our general and administrative functions for the six-months ended June 30, 2023 and 2022 constituted approximately 57% and 56%, respectively, of our general and administrative costs.
We expect selling, general and administrative costs to increase moderately in 2023 as compared to 2022 due to our recent sales force expansion and increased marketing, promotional and advertising costs.
Research and Development Expenses
The following tables set forth our research and development expenses for the three and six-month periods ended June 30, 2023 and 2022 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
External service costs$37,727 $26,920 $65,456 $47,147 
Internal and other costs12,067 11,616 22,362 20,432 
Total research and development expenses$49,794 $38,536 $87,818 $67,579 
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Lumateperone costs$31,267 $22,137 $55,361 $39,610 
Non-lumateperone costs10,522 8,022 18,056 14,264 
Overhead and other costs8,005 8,377 14,401 13,705 
Total research and development expenses$49,794 $38,536 $87,818 $67,579 
Research and development expenses increased to $49.8 million for the three-month period ended June 30, 2023 as compared to $38.5 million for the three-month period ended June 30, 2022, representing an increase of $11.3 million, or 29%. This increase is due primarily to an increase of $9.1 million for lumateperone project costs, $2.5 million for non-lumateperone projects, and is partially offset by a decrease of $0.3 million for overhead and other costs. External service costs increased by $10.8 million for the period due to the increased lumateperone and non-lumateperone project costs. Internal and other costs increased by $0.5 million for the period due primarily to labor related costs and share-based compensation.
19
Research and development expenses increased to $87.8 million for the six-month period ended June 30, 2023 as compared to $67.6 million for the six-month period ended June 30, 2022, representing an increase of $20.2 million, or 30%. This increase is due primarily to an increase of $15.8 million for lumateperone project costs, $3.8 million for non-lumateperone projects, and $0.6 million for overhead and other costs. External service costs increased by $18.3 million for the period due to the increased lumateperone and non-lumateperone project costs. Internal and other costs increased by $1.9 million for the period due primarily to labor related costs and share-based compensation.
The successful development of our product candidates and the approval process requires substantial time, effort and financial resources, and is uncertain and subject to a number of risks. We cannot be certain that any of our product candidates will prove to be safe and effective, will meet all of the applicable regulatory requirements needed to receive and maintain marketing approval, or will be granted marketing approval on a timely basis, if at all. Data from non-clinical studies and clinical trials are susceptible to varying interpretations that could delay, limit or prevent regulatory approval or could result in label warnings related to or recalls of approved products. We, the FDA, or other regulatory authorities may suspend clinical trials at any time if we or they believe that the subjects participating in such trials are being exposed to unacceptable risks or if such regulatory agencies find deficiencies in the conduct of the trials or other problems with our product candidates. Other risks associated with our product candidates are described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, as updated by the section titled “Risk Factors” in this Quarterly Report on Form 10-Q and from time to time in our other periodic and current reports filed with the SEC.
Liquidity and Capital Resources
Since our inception, we have incurred significant operating and cash losses from our operations. We have primarily funded our operations to date through proceeds from public and private offerings of our common stock and other securities, and to a far lesser extent, through proceeds from grants from government agencies and foundations. In addition, we began to generate net product revenue in the first quarter of 2020 in conjunction with the commercial launch of CAPLYTA.
As of June 30, 2023, our cash and cash equivalents, available-for-sale investment securities, and restricted cash totaled $514.6 million. We invest cash in excess of our immediate requirements with regard to liquidity and capital preservation in a variety of interest-bearing instruments, including obligations of U.S. government agencies and money market accounts. Wherever possible, we seek to minimize the potential effects of concentration and degrees of risk. Although we maintain cash balances and investments with financial institutions in excess of insured limits, we do not anticipate any losses with respect to such balances.
During the six-months ended June 30, 2023, we used $96.9 million of net cash in operating activities, a decrease of $80.8 million as compared to the six-months ended June 30, 2022. The decrease in net cash used in operations was primarily due to higher sales and resulting lower net loss in the current period as compared to the prior period. The primary uses of cash were for selling and marketing costs in connection with our commercialization of CAPLYTA, conducting clinical trials and non-clinical testing, funding recurring operating expenses, and product manufacturing.
Based on our current operating plans, we expect that our existing cash, cash equivalents, marketable securities, and product sales will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the filing date of this quarterly report. During that time, we expect that our expenses will increase, primarily due to the continued commercialization of CAPLYTA for the treatment of schizophrenia and bipolar depression; the development of lumateperone in our late-stage clinical programs; the development of our other product candidates and programs, including PDE, ITI-1284, and ITI-333; and infrastructure expansion and general operations.
We seek to balance the level of cash, cash equivalents and investments on hand with our projected needs and to allow us to withstand periods of uncertainty relative to the availability of funding on favorable terms. Subject to our ability to generate significant revenues from operations, we may need to satisfy our future cash needs through public or private sales of our equity securities, sales of debt securities, incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of our product candidates and technology and, to a lesser extent, grant funding.
20
We cannot be sure that future funding will be available to us when we need it on terms that are acceptable to us, or at all. We sell securities and incur debt when the terms of such transactions are deemed favorable to us and as necessary to fund our current and projected cash needs. The amount of funding we raise through sales of our common stock or other securities depends on many factors, including, but not limited to, the magnitude of sales of CAPLYTA, the status and progress of our product development programs, projected cash needs, availability of funding from other sources, our stock price and the status of the capital markets. Due to the volatile nature of the financial markets, equity and debt financing may be difficult to obtain.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.
If adequate funds are not available to us on a timely basis, we may be required to: (1) delay, limit, reduce or terminate non-clinical studies, clinical trials or other clinical development activities for one or more of our product candidates, including our lead product candidate lumateperone and our other product candidates; (2) delay, limit, reduce or terminate our discovery research or non-clinical development activities; (3) enter into licenses or other arrangements with third parties on terms that may be unfavorable to us or sell, license or relinquish rights to develop or commercialize our product candidates, technologies or intellectual property at an earlier stage of development and on less favorable terms than we would otherwise agree; or (4) limit or reduce commercialization efforts related to CAPLYTA.
Our cash is maintained in checking accounts, money market accounts, money market mutual funds, U.S. government agency securities, certificates of deposit, commercial paper, corporate notes and corporate bonds at major financial institutions. Since early 2022, interest rates have risen which is increasing our interest income. During 2023, there was a decrease in unrealized loss due to interest rate fluctuations and maturities. This gain resulted in a lower net unrealized loss balance of $2.3 million as of June 30, 2023. Due to the short-term nature of these investments and our intention to hold these investments to maturity, we do not expect to recognize these losses. Even with the rise or further potential rise in interest rates, we do not expect interest income to be a significant source of funding. In addition, our investment portfolio historically has not been adversely impacted by problems in the credit markets, but there can be no assurance that our investment portfolio will not be adversely affected in the future.
Our cash requirements in the short and long term consist primarily of operational and manufacturing expenditures, a portion of which contain contractual or other obligations. We plan to fund our cash requirements with our current financial resources together with our anticipated receipts from product sales. We manage future cash requirements relative to our long-term business plans. Our primary uses of cash relate to marketing and manufacturing our products, paying employees and consultants, administering clinical trials, and providing technology and facility infrastructure to support our operations.
We have three kinds of long-term contractual commitments - operating leases, licensing and royalty commitments, and purchase obligations. Our operating lease for approximately 32,000 square feet of useable laboratory and office space, as amended, has a term of 14.3 years ending in May 2029.
We entered into an exclusive license with Bristol-Myers Squibb Company (BMS), for which we are obligated to make tiered single-digit percentage royalty payments on sales of licensed products. The amount of future royalty obligations are dependent on future net product sales of the licensed product. The Company may also be obligated to make other milestone payments to BMS for each licensed product of up to an aggregate of $14.75 million.
21
In addition, we have entered into certain other long-term commitments for goods and services that are outstanding for periods greater than one year. We recently amended certain manufacturing service agreements committing the Company to certain minimum annual purchase commitments for which we anticipate payments being made within the years 2025 through 2029. We also have entered into short-term agreements with various vendors and suppliers of goods and services in the normal course of operations through purchase orders. Such short-term agreements are generally outstanding for periods less than a year and are settled by cash payments upon delivery of goods and services. The nature of the work being conducted under these agreements is such that, in most cases, the services may be stopped on short notice without penalty. In such event, we would not be liable for the full amount of the agreement. We also have entered into clinical trial agreements which may span over multiple years.
Critical Accounting Policies and Estimates
Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our condensed consolidated financial statements. We evaluate our estimates, judgments, and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes to our critical accounting policies during the six-month period ended June 30, 2023.
The discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires management to make estimates and assumptions that affect reported amounts of assets and liabilities as of the date of the balance sheet and reported amounts of revenues and expenses for the periods presented. Judgments must also be made about the disclosure of contingent liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management makes estimates and exercises judgment in research and development, including clinical trial accruals. Actual results may differ from those estimates and under different assumptions or conditions.
Recently Issued Accounting Pronouncements
We review new accounting standards to determine the expected financial impact, if any, that the adoption of each such standard will have. Based on our assessment, all new accounting pronouncements were determined to be either not applicable or are expected to have minimal impact on our consolidated financial statements or related disclosures.
22
Certain Factors That May Affect Future Results of Operations
The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Quarterly Report on Form 10-Q contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other important factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: the accuracy of our estimates regarding expenses, revenues, uses of cash, cash equivalents and investment securities, capital requirements and the need for additional financing; our expectations regarding our commercialization of CAPLYTA; the duration and severity of the COVID-19 pandemic and its continued impact on our business; the supply and availability of and demand for our product; the initiation, cost, timing, progress and results of our development activities, pre-clinical studies and clinical trials; the timing of and our ability to obtain and maintain regulatory approval, or submit an application for regulatory approval, of lumateperone and our other existing product candidates, any product candidates that we may develop, and any related restrictions, limitations, and/or warnings in the label of any approved product candidates; our plans to research, develop and commercialize lumateperone and our other current and future product candidates; the election by any collaborator to pursue research, development and commercialization activities; our ability to obtain future reimbursement and/or milestone payments from our collaborators; our ability to attract collaborators with development, regulatory and commercialization expertise; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to successfully commercialize lumateperone and our other product candidates; the performance of our third-party suppliers and manufacturers and our ability to obtain alternative sources of raw materials; our ability to obtain additional financing; our use of the proceeds from our securities offerings; our exposure to investment risk, interest rate risk, inflation risk, capital market risk, and geopolitical instability; and our ability to attract and retain key scientific, management, or sales and marketing personnel.
Words such as “may,” “anticipate,” “estimate,” “expect,” “may,” “project,” “intend,” “plan,” “believe,” “potential,” “predict,” “project,” “likely,” “will,” “would,” “could,” “should,” “continue” and words and terms of similar substance used in connection with any discussion of future operating or financial performance, identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: there are no guarantees that CAPLYTA will be commercially successful; we may encounter issues, delays or other challenges in commercializing CAPLYTA; the COVID-19 pandemic may negatively impact our commercial plans and sales for CAPLYTA; the COVID-19 pandemic may negatively impact the conduct of, and the timing of enrollment, completion and reporting with respect to, our clinical trials; whether CAPLYTA receives adequate reimbursement from third-party payors; the degree to which CAPLYTA receives acceptance from patients and physicians for its approved indications; challenges associated with execution of our sales activities, which in each case could limit the potential of our product; results achieved in CAPLYTA in the treatment of schizophrenia and bipolar depression following commercial launch of the product may be different than observed in clinical trials, and may vary among patients; any other impacts on our business as a result of or related to the COVID-19 pandemic; challenges associated with supply and manufacturing activities, which in each case could limit our sales and the availability of our product; impacts on our business, including on the commercialization of CAPLYTA and our clinical trials, as a result of the conflict in Ukraine; risks associated with our current and planned clinical trials; we may encounter unexpected safety or tolerability issues with CAPLYTA following commercial launch for the treatment of schizophrenia or bipolar depression or in ongoing or future trials and other development activities; our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials or in clinical trials for other indications; our proposals with respect to the regulatory path for our product candidates may not be acceptable to the FDA; our reliance on collaborative partners and other third parties for development, commercialization, manufacturing or supply of our product and product candidates; risks related to increased interest rates, high rates of inflation, global supply chain disruptions, and geopolitical instability on our business; and the other risk factors detailed under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, as updated under the heading “Risk Factors” from time to time in our subsequent periodic and current reports filed with the SEC.
23
In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report on Form 10-Q or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to the Company or to any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.
Item 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Sensitivity. As of June 30, 2023, we had cash, cash equivalents, marketable securities and restricted cash of $514.6 million consisting of cash deposited in a highly rated financial institution in the United States and in a short-term U.S. Treasury money market fund, as well as high-grade corporate bonds and commercial paper. The primary objective of our investment activities is to preserve our capital for the purpose of funding operations and we do not enter into investments for trading or speculative purposes. We believe that we do not have material exposure to high-risk investments such as mortgage-backed securities, auction rate securities or other special investment vehicles within our money-market fund investments. We believe that we do not have any material exposure to changes in fair value as a result of changes in interest rates. Since early 2022, interest rates have risen which is increasing our interest income. During 2023, there was a decrease in unrealized loss due to interest rate fluctuations and maturities. This gain resulted in a lower net unrealized loss balance of $2.3 million as of June 30, 2023.
Inflation Risk. Inflation generally may affect us by increasing our cost of labor, clinical trial costs, and costs of other outsourced activities. To date, inflation has not had a material impact on our business, but if the global inflationary trends continue, we expect appreciable increases in clinical trial, selling, labor, and other operating costs. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases of our product or cash flows from other sources. Our inability or failure to do so could adversely affect our business, financial condition and results of operations.
Capital Market Risk. Although we receive product revenues from commercial sales of CAPLYTA, we continue to assess the need for additional funding through other sources. One possible source of funding is through further equity offerings. Our ability to raise funds in this manner depends upon capital market forces affecting our stock price.
Item 4.    CONTROLS AND PROCEDURES
(a) Evaluation of Disclosure Controls and Procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were effective at a reasonable assurance level to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
(b) Changes in Internal Controls. There were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control that occurred during the three-month period ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
24
PART II: OTHER INFORMATION
Item 1.    LEGAL PROCEEDINGS

On July 8, 2022, a purported shareholder derivative complaint was filed in the Supreme Court for the State of New York against the directors serving on the Company’s board of directors and the Company as a nominal defendant alleging breach of fiduciary duty and unjust enrichment alleging that compensation awarded to the director defendants for service on the board of directors was excessive. On March 6, 2023, the parties filed a stipulation of settlement (the “Stipulation”). The Stipulation does not require any damages payments or disgorgement by defendants or the Company. The Stipulation provides that, going forward, the board of directors will amend its compensation policies for non-employee directors, including, inter alia, by capping annual equity compensation at the 75th percentile of the annual equity grants for a peer group of companies. Subject to the terms and conditions of the Stipulation and final approval of the Court, the Company and/or its insurance carriers have agreed to pay up to $375,000 in attorneys’ fees to plaintiff’s counsel. On April 12, 2023, the court granted preliminary approval of the settlement and on July 17, 2023 the court approved the Stipulation.
Item 1A.    RISK FACTORS
There have been no material changes to the risk factors discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 1, 2023.
Item 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Unregistered Sales of Equity Securities
Not applicable.
Issuer Purchases of Equity Securities
We did not repurchase any of our equity securities during the quarter ended June 30, 2023.
Item 3.    DEFAULTS UPON SENIOR SECURITIES
Not applicable.
Item 4.    MINE SAFETY DISCLOSURES
Not applicable.
Item 5.    OTHER INFORMATION

During the fiscal quarter ended June 30, 2023, the following director and executive officers modified "Rule 10b5-1 trading arrangements" (as defined in Item 408 of Regulation S-K of the Exchange Act):

•On May 8, 2023, Michael I. Halstead, Executive Vice President, General Counsel and Secretary, modified his Rule 10b5-1 Trading Plan, originally adopted on March 15, 2023, to change the start date of the plan to January 2, 2024, and reduce the number of shares to be sold under the plan. The modified plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 37,872 shares of our common stock until March 28, 2024.

•On June 9, 2023, Sharon Mates, Ph.D., Chairman, President and Chief Executive Officer, modified her Rule 10b5-1 Trading Plan, originally adopted on March 14, 2023, to change the start date to September 18, 2023 and the end date of the plan to May 31, 2024, and reduce the number of shares to be sold under the plan. The modified plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 402,337 shares of our common stock including the potential sale of up to 191,362 shares of our common stock upon the exercise of stock options with an exercise expiration date of June 30, 2024. Furthermore, we expect a significant portion of the proceeds from any sales under the plan will be used to cover Dr. Mates' tax liability arising from such sales.

25
There were no "non-Rule 10b5-1 trading arrangements" (as defined in Item 408 of Regulation S-K of the Exchange Act) adopted, modified or terminated during the fiscal quarter ended June 30, 2023 by our directors and executive officers.
26
Item 6.    EXHIBITS
Exhibit
Number
Exhibit Description
Filed
Herewith
Incorporated by
Reference herein
from Form
or Schedule
Filing Date
SEC File/
Reg. Number
10.110-K
(Exhibit 10.1)		5/4/2023001-36274
31.1X
31.2X
32X
101
The following materials from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of June 30, 2023 (unaudited) and December 31, 2022 (audited), (ii) Condensed Consolidated Statements of Operations (unaudited) for the three and six months ended June 30, 2023 and 2022, (iii) Condensed Consolidated Statements of Comprehensive Loss (unaudited) for the three and six months ended June 30, 2023 and 2022, (iv) Condensed Consolidated Statements of Stockholders’ Equity (unaudited) for the three and six months ended June 30, 2023 and 2022, (v) Condensed Consolidated Statements of Cash Flows (unaudited) for the six months ended June 30, 2023 and 2022, and (vi) Notes to Condensed Consolidated Financial Statements (unaudited).
X
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).X
* Management contract or compensatory plan or arrangement.

27
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
INTRA-CELLULAR THERAPIES, INC.
Date: August 3, 2023
By:/s/ Sharon Mates, Ph.D.
Sharon Mates, Ph.D.
Chairman, President and Chief Executive Officer
Date: August 3, 2023
By:/s/ Lawrence J. Hineline
Lawrence J. Hineline
Senior Vice President of Finance and Chief Financial Officer
28
 EX-31.1 2 itci-20230630xex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATIONS UNDER SECTION 302
I, Sharon Mates, Ph.D., certify that:
1.I have reviewed this quarterly report on Form 10-Q of Intra-Cellular Therapies, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 3, 2023
/s/ Sharon Mates, Ph.D.
Sharon Mates, Ph.D.
Chairman, President and Chief Executive Officer
(principal executive officer)

 EX-31.2 3 itci-20230630xex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATIONS UNDER SECTION 302
I, Lawrence J. Hineline, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Intra-Cellular Therapies, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 3, 2023
/s/ Lawrence J. Hineline
Lawrence J. Hineline
Senior Vice President of Finance and Chief Financial Officer
(principal financial officer)

 EX-32 4 itci-20230630xex32.htm EX-32 Document

Exhibit 32
CERTIFICATIONS UNDER SECTION 906
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Intra-Cellular Therapies, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Quarterly Report for the quarter ended June 30, 2023 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: August 3, 2023
/s/ Sharon Mates, Ph.D.
Sharon Mates, Ph.D.
Chairman, President and Chief Executive Officer
(principal executive officer)
Dated: August 3, 2023
/s/ Lawrence J. Hineline
Lawrence J. Hineline
Senior Vice President of Finance and Chief Financial Officer
(principal financial officer)

EX-101.SCH 5 itci-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Investment Securities link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Right of Use Assets and Lease Liabilities link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 9954701 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954702 - Disclosure - Investment Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954703 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954704 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954705 - Disclosure - Right of Use Assets and Lease Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954706 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954707 - Disclosure - Loss Per Share - (Tables) link:presentationLink link:calculationLink link:definitionLink 9954708 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954709 - Disclosure - Investment Securities - Summary of Investment Securities (Detail) link:presentationLink link:calculationLink link:definitionLink 9954710 - Disclosure - Investment Securities - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954711 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954712 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) link:presentationLink link:calculationLink link:definitionLink 9954713 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) link:presentationLink link:calculationLink link:definitionLink 9954714 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954715 - Disclosure - Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 9954716 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) link:presentationLink link:calculationLink link:definitionLink 9954717 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954718 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 9954719 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 9954720 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) link:presentationLink link:calculationLink link:definitionLink 9954721 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954722 - Disclosure - Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 itci-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 itci-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 itci-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] Range [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Outstanding at beginning of year, Number of Shares (in shares) Outstanding at end of year, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Schedule of Investment Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Corporate Notes/Bonds Corporate Debt Securities [Member] Purchases of investments Payments to Acquire Investments Insider Trading Policies and Procedures [Line Items] Exercisable at end of period, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Proceeds of public offering, net Proceeds from Issuance of Common Stock Right of Use Assets and Lease Liabilities Right Of Use Assets And Lease Liabilities [Text Block] Right of use assets and lease liabilities. Exercise of stock options and issuances of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Weighted-Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Vested or expected to vest at end of period, Weighted-Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Outstanding at beginning of period, Number of Shares (in shares) Outstanding at end of period, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Accrued employee benefits Accrued Employee Benefits, Current Trading Symbol Trading Symbol U.S. Government Agency Securities US Government Agencies Debt Securities [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Payment of milestone amount Possible Milestone Payments Remaining Payment of milestone amount. Purchase Commitment Purchase Commitment [Member] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Unrealized (Losses) Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Options exercised, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Executive Category: Executive Category [Axis] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Certificates of Deposit Certificates of Deposit [Member] Investment Type [Axis] Investment Type [Axis] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Investments [Domain] Investments [Domain] Local Phone Number Local Phone Number Accounts receivable, net Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Selling, general and administrative Selling, General and Administrative Expenses [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Operating lease liabilities, non-current Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Thereafter Lessee Operating Lease Liability Payments Due after Year Four Lessee operating lease liability payments due after Year four. RSUs Restricted Stock Units (RSUs) [Member] Summary of Information Regarding RSU Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation Depreciation Income Statement Location [Axis] Income Statement Location [Axis] Purchase Commitment, Excluding Long-Term Commitment [Axis] Purchase Commitment, Excluding Long-Term Commitment [Axis] Schedule Of Maturity Analysis Under Lease Agreements Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] FDIC Certificates of Deposit FDIC Certificates Of Deposit [Member] FDIC certificates of deposit. Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventory Increase (Decrease) in Inventories Unrealized gain (loss) on investment securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Research and development Research and Development Expense [Member] Cash flows provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Schedule of Quantitative Information About Operating Leases Schedule of Quantitative Information About Operating Leases [Table Text Block] Schedule of Quantitative Information About Operating Leases Number of anti-dilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Time based RSU's granted, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Non-cash investing and financing activities Noncash Investing and Financing Items [Abstract] Unrecognized compensation costs related to unvested RSUs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Outstanding at end of period, Weighted-Average Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Right of use assets under operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Trading Arrangement: Trading Arrangement [Axis] Less: Present value discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Operating lease liabilities Less: Current portion Operating Lease, Liability, Current Entity Shell Company Entity Shell Company Year ending December 31, 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Asset Class [Axis] Asset Class [Axis] Year ending December 31, 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Variable lease cost Variable Lease, Cost Operating lease cost Operating Lease, Cost Weighted average number of common shares: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Aggregate fair value of investments with unrealized losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Common stock, shares issued (in shares) Common Stock, Shares, Issued Time based RSU's vested, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Maturities of investments Proceeds from Sale, Maturity and Collection of Investments Security Exchange Name Security Exchange Name Assets measured using quoted prices Available-for-sale investment securities Assets, Fair Value Disclosure Percentage of fair value instruments Debt Securities, Available For Sale, Unrealized Losses, Percentage Of Fair Value Of Investments Debt Securities, Available For Sale, Unrealized Losses, Percentage Of Fair Value Of Investments Accumulated comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Carrying value of cash held in commercial paper, government securities US Government Agencies Securities, at Carrying Value Stock options Share-Based Payment Arrangement, Option [Member] Employee Stock Option [Member] Maximum Maximum [Member] Customer Three Customer Three [Member] Customer three. Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Short-term lease cost Short-Term Lease, Cost Entity Address, Address Line One Entity Address, Address Line One Accrued and other current liabilities Accrued Liabilities and Other Liabilities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Share-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Customer Concentration Risk Customer Concentration Risk [Member] Customer Two Customer Two [Member] Customer two. Income Statement [Abstract] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Common shares issued (in shares) Stock Issued During Period, Shares, New Issues Operating expenses: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Outstanding at beginning of year, Weighted-Average Grant Date Fair Value (in dollars per share) Outstanding at end of year, Weighted-Average Grant Date Fair Value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventory Total inventories Inventory, Net Total lease cost Lease, Cost Range [Axis] Statistical Measurement [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Product sales, net Product Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Cash flows used in operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant accounting policies. Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Customer One Customer One [Member] Customer one. Certificates of deposits Certificates of Deposit, at Carrying Value PEO PEO [Member] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Asset Class [Domain] Asset Class [Domain] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Company made an upfront payment Collaborative Agreement Upfront Payments Collaborative Agreement Upfront Payments Name of Property [Domain] Name of Property [Domain] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Total operating lease liability Operating Lease, Liability Total liabilities Liabilities Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Aggregate related fair value of investments with unrealized losses Debt Securities, Available-for-Sale, Unrealized Loss Position Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Net loss per common share: Earnings Per Share [Abstract] Other information Other Information [Abstract] Other information. Common stock, $0.0001 par value: 175,000,000 shares authorized at June 30, 2023 and December 31, 2022; 96,083,387 and 94,829,794 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Continuous unrealized losses, value remaining Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Selling, general and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Stock issued for services Issuance of Stock and Warrants for Services or Claims All Individuals All Individuals [Member] Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date PEO Name PEO Name Concentration risk (as a percent) Concentration Risk, Percentage Time based RSU's granted, Weighted-Average Grant Date Fair Value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Restricted cash Restricted Cash, Current Significant Accounting Policies Significant Accounting Policies [Policy Text Block] Significant accounting policies. Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Investment securities, available-for-sale Debt Securities, Available-for-Sale, Current Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Accrued employee benefits Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Commercial Paper Commercial Paper [Member] Obliged to make milestone payments Collaborative Arrangement Amount Payable Collaborative arrangement amount payable. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Revenue Recognition, Multiple-deliverable Arrangements [Table] Revenue Recognition, Multiple-deliverable Arrangements [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Year ending December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Accrued and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Year ending December 31, 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Outstanding at beginning of period, Weighted-Average Exercise Price (in dollars per share) Outstanding at end of period, Weighted-Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation Total share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Options granted, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Investment securities, available for sale, noncurrent Debt Securities, Available-for-Sale, Noncurrent Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Loss Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Term of long term lease Lessee, Operating Lease, Term of Contract Minimum Minimum [Member] Property and equipment, net Property, Plant and Equipment, Net Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Cash paid Cash Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Liabilities measured using quoted prices Liabilities, Fair Value Disclosure Operating lease liabilities, net Increase (Decrease) in Operating Lease Liability Sharon Mates [Member] Sharon Mates Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Share-Based Payment Arrangement, Expensed and Capitalized, Amount Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Amortization of premiums and accretion of discounts on investment securities, net Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and stockholders’ equity Liabilities and Equity Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Basic (in dollars per share) Earnings Per Share, Basic Right of use assets, net Operating Lease, Right-of-Use Asset Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Six months ending December 31, 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Purchase Commitment, Excluding Long-Term Commitment [Domain] Purchase Commitment, Excluding Long-Term Commitment [Domain] Michael I. Halstead [Member] Michael I. Halstead Stock issued for services Stock Issued During Period, Value, Issued for Services Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Cost of product sales Cost Of Product Sales Cost of product sales. Termination Date Trading Arrangement Termination Date Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Estimated Fair Value Debt Securities, Available-for-Sale Inventoriable costs Inventoriable Costs [Member] InventoriableCostsMember. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Accrued customer programs Increase Decrease In Accrued Customer Programs Increase decrease in accrued customer programs. Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Commercial paper value listed as cash equivalent Commercial Paper, at Carrying Value NEW YORK NEW YORK Investment Securities Investment [Text Block] Compensation Amount Outstanding Recovery Compensation Amount Other comprehensive gain (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Time based RSU's cancelled, Weighted-Average Grant Date Fair Value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Proceeds from exercise of stock options Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Time based RSU's cancelled, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Insider Trading Arrangements [Line Items] Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Exercise of stock options and issuances of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Exercisable at end of period, Weighted-Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key License expiration period Collaborative Arrangement License Expiration Term Collaborative arrangement license expiration description. Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax expense Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Restricted stock outstanding, Weighted-Average Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Time Based Restricted Stock Units Time Based Restricted Stock Units R S U [Member] Time based restricted stock units. Fair Value Measurements Fair Value Disclosures [Text Block] Number of operating segments Number of Operating Segments Revenue Benchmark Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Common shares issued Stock Issued During Period, Value, New Issues Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Inventory Inventory Disclosure [Text Block] Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Total revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag Money Market Funds Money Market Funds [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Weighted average discount rate (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Stock issued for services (in shares) Stock Issued During Period, Shares, Issued for Services Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Royalty payment, percentage (as a percent) Royalty Payment Percentage Royalty Payment Percentage Diluted (in share) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Carrying value of cash held in money market funds Money Market Funds, at Carrying Value Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Vehicle Lease Vehicles [Member] Lease cost Lease, Cost [Abstract] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Cover [Abstract] Cover [Abstract] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Grant revenue Grant [Member] Time based RSU's vested, Weighted-Average Grant Date Fair Value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Options canceled or expired, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Total Lessee, Operating Lease, Liability, to be Paid Total operating expenses Operating Expenses Net decrease in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows provided by financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Work in process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Three Major Wholesalers Three Major Wholesalers [Member] Three Major Wholesalers Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Loss from operations Operating Income (Loss) Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Bristol-Myers Squibb Company Bristol Myers Squibb Company [Member] Bristol Myers Squibb company. Cash and Cash Equivalents Cash and Cash Equivalents [Member] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Vested or expected to vest at end of period, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Accrued customer programs Accrued Customer Programs Current Accrued customer programs current. Guarantor obligations, value Guarantor Obligations, Current Carrying Value Name of Property [Axis] Name of Property [Axis] EX-101.PRE 9 itci-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page - shares
 6 Months Ended
Jun. 30, 2023
Aug. 01, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2023  
Document Transition Report false  
Entity File Number 001-36274  
Entity Registrant Name INTRA-CELLULAR THERAPIES, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 36-4742850  
Entity Address, Address Line One 430 East 29th Street  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10016  
City Area Code 646  
Local Phone Number 440-9333  
Title of 12(b) Security Common Stock  
Trading Symbol ITCI  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   96,091,564
Entity Central Index Key 0001567514  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Amendment Flag false  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 142,258 $ 148,615
Investment securities, available-for-sale 370,596 443,290
Restricted cash 1,750 1,750
Accounts receivable, net 95,964 75,189
Inventory 41,895 23,920
Prepaid expenses and other current assets 45,610 45,193
Total current assets 698,073 737,957
Property and equipment, net 1,656 1,913
Right of use assets, net 13,787 14,824
Other assets 86 86
Total assets 713,602 754,780
Current liabilities:    
Accounts payable 7,733 10,395
Accrued and other current liabilities 27,456 19,657
Accrued customer programs 31,710 25,621
Accrued employee benefits 21,623 22,996
Operating lease liabilities 3,558 4,567
Total current liabilities 92,080 83,236
Operating lease liabilities, non-current 14,432 15,474
Total liabilities 106,512 98,710
Stockholders’ equity:    
Common stock, $0.0001 par value: 175,000,000 shares authorized at June 30, 2023 and December 31, 2022; 96,083,387 and 94,829,794 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively 10 9
Additional paid-in capital 2,173,671 2,137,737
Accumulated deficit (1,564,323) (1,477,486)
Accumulated comprehensive loss (2,268) (4,190)
Total stockholders’ equity 607,090 656,070
Total liabilities and stockholders’ equity $ 713,602 $ 754,780
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 175,000,000 175,000,000
Common stock, shares issued (in shares) 96,083,387 94,829,794
Common stock, shares outstanding (in shares) 96,083,387 94,829,794
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Total revenues, net $ 110,792 $ 55,579 $ 206,098 $ 90,575
Operating expenses:        
Cost of product sales 7,163 4,650 13,914 7,805
Selling, general and administrative 101,014 100,316 199,937 175,776
Research and development 49,794 38,536 87,818 67,579
Total operating expenses 157,971 143,502 301,669 251,160
Loss from operations (47,179) (87,923) (95,571) (160,585)
Interest income 4,530 1,320 8,879 1,868
Loss before provision for income taxes (42,649) (86,603) (86,692) (158,717)
Income tax expense (135) 0 (145) (5)
Net loss $ (42,784) $ (86,603) $ (86,837) $ (158,722)
Net loss per common share:        
Basic (in dollars per share) $ (0.45) $ (0.92) $ (0.91) $ (1.70)
Diluted (in dollars per share) $ (0.45) $ (0.92) $ (0.91) $ (1.70)
Weighted average number of common shares:        
Basic (in shares) 95,948,063 94,285,117 95,543,626 93,449,424
Diluted (in share) 95,948,063 94,285,117 95,543,626 93,449,424
Product sales, net        
Total revenues, net $ 110,128 $ 55,074 $ 204,859 $ 89,829
Grant revenue        
Total revenues, net $ 664 $ 505 $ 1,239 $ 746
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net loss $ (42,784) $ (86,603) $ (86,837) $ (158,722)
Other comprehensive gain (loss):        
Unrealized gain (loss) on investment securities 430 (1,474) 1,922 (4,438)
Comprehensive loss $ (42,354) $ (88,077) $ (84,915) $ (163,160)
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Comprehensive (Loss) Income
Beginning balance at Dec. 31, 2021 $ 417,890 $ 8 $ 1,639,476 $ (1,221,230) $ (364)
Beginning balance (in shares) at Dec. 31, 2021   81,886,965      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common shares issued (in shares)   10,952,381      
Common shares issued 433,725 $ 1 433,724    
Exercise of stock options and issuances of restricted stock (in shares)   1,180,696      
Exercise of stock options and issuances of restricted stock 8,089   8,089    
Stock issued for services (in shares)   383      
Stock issued for services 24   24    
Share-based compensation 8,105   8,105    
Net loss (72,119)     (72,119)  
Other comprehensive loss (2,964)       (2,964)
Ending balance at Mar. 31, 2022 792,750 $ 9 2,089,418 (1,293,349) (3,328)
Ending balance (in shares) at Mar. 31, 2022   94,020,425      
Beginning balance at Dec. 31, 2021 417,890 $ 8 1,639,476 (1,221,230) (364)
Beginning balance (in shares) at Dec. 31, 2021   81,886,965      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (158,722)        
Ending balance at Jun. 30, 2022 722,197 $ 9 2,106,942 (1,379,952) (4,802)
Ending balance (in shares) at Jun. 30, 2022   94,367,233      
Beginning balance at Mar. 31, 2022 792,750 $ 9 2,089,418 (1,293,349) (3,328)
Beginning balance (in shares) at Mar. 31, 2022   94,020,425      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common shares issued (in shares)   346,411      
Common shares issued 5,504   5,504    
Exercise of stock options and issuances of restricted stock (in shares)   397      
Exercise of stock options and issuances of restricted stock 22   22    
Share-based compensation 11,998   11,998    
Net loss (86,603)     (86,603)  
Other comprehensive loss (1,474)       (1,474)
Ending balance at Jun. 30, 2022 722,197 $ 9 2,106,942 (1,379,952) (4,802)
Ending balance (in shares) at Jun. 30, 2022   94,367,233      
Beginning balance at Dec. 31, 2022 656,070 $ 9 2,137,737 (1,477,486) (4,190)
Beginning balance (in shares) at Dec. 31, 2022   94,829,794      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and issuances of restricted stock (in shares)   849,827      
Exercise of stock options and issuances of restricted stock 3,640 $ 1 3,639    
Stock issued for services (in shares)   408      
Stock issued for services 22   22    
Share-based compensation 10,439   10,439    
Net loss (44,053)     (44,053)  
Other comprehensive loss 1,492       1,492
Ending balance at Mar. 31, 2023 627,610 $ 10 2,151,837 (1,521,539) (2,698)
Ending balance (in shares) at Mar. 31, 2023   95,680,029      
Beginning balance at Dec. 31, 2022 656,070 $ 9 2,137,737 (1,477,486) (4,190)
Beginning balance (in shares) at Dec. 31, 2022   94,829,794      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (86,837)        
Ending balance at Jun. 30, 2023 607,090 $ 10 2,173,671 (1,564,323) (2,268)
Ending balance (in shares) at Jun. 30, 2023   96,083,387      
Beginning balance at Mar. 31, 2023 627,610 $ 10 2,151,837 (1,521,539) (2,698)
Beginning balance (in shares) at Mar. 31, 2023   95,680,029      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and issuances of restricted stock (in shares)   402,994      
Exercise of stock options and issuances of restricted stock 8,585   8,585    
Stock issued for services (in shares)   364      
Stock issued for services 23   23    
Share-based compensation 13,226   13,226    
Net loss (42,784)     (42,784)  
Other comprehensive loss 430       430
Ending balance at Jun. 30, 2023 $ 607,090 $ 10 $ 2,173,671 $ (1,564,323) $ (2,268)
Ending balance (in shares) at Jun. 30, 2023   96,083,387      
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows used in operating activities    
Net loss $ (86,837) $ (158,722)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 257 343
Share-based compensation 23,665 20,103
Stock issued for services 45 46
Amortization of premiums and accretion of discounts on investment securities, net (3,670) (947)
Changes in operating assets and liabilities:    
Accounts receivable, net (20,775) (26,820)
Inventory (17,975) (17,074)
Prepaid expenses and other assets (417) (12,535)
Accounts payable (2,662) 2,058
Accrued and other current liabilities 7,799 6,201
Accrued customer programs 6,089 10,519
Accrued employee benefits (1,373) (2,512)
Operating lease liabilities, net (1,014) 1,698
Net cash used in operating activities (96,868) (177,642)
Cash flows provided by (used in) investing activities    
Purchases of investments (174,411) (552,782)
Maturities of investments 252,697 268,665
Purchases of property and equipment 0 (689)
Net cash provided by (used in) investing activities 78,286 (284,806)
Cash flows provided by financing activities    
Proceeds of public offering, net 0 433,725
Proceeds from exercise of stock options 12,225 13,593
Net cash provided by financing activities 12,225 447,318
Net decrease in cash, cash equivalents, and restricted cash (6,357) (15,130)
Cash, cash equivalents, and restricted cash at beginning of period 150,365 93,765
Cash, cash equivalents, and restricted cash at end of period 144,008 78,635
Non-cash investing and financing activities    
Right of use assets under operating leases $ 0 $ 4,167
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Jun. 30, 2022
Dec. 31, 2021
Statement of Cash Flows [Abstract]        
Cash and cash equivalents $ 142,258 $ 148,615 $ 77,235  
Restricted cash 1,750 1,750 1,400  
Total cash, cash equivalents and restricted cash $ 144,008 $ 150,365 $ 78,635 $ 93,765
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Organization
 6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiary, ITI, Inc. (“ITI”), is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (“CNS”). In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42mg/day) and the Company initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42mg/day). The Company initiated the commercial launch of CAPLYTA for the treatment of bipolar depression in December 2021. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). The commercial launch of these special population doses occurred in August 2022. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression. Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder. In order to further its commercial activities and research projects and support its collaborations, the Company may require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt or convertible debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s products, product candidates and technology and, to a much lesser extent, grant funding.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders.
Recent Accounting Pronouncements
Management has evaluated all accounting pronouncements issued through the date of the condensed consolidated financial statements and does not believe that any recently issued, but not yet effective, pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Significant Accounting Policies
The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. As of June 30, 2023, the majority of the Company’s accounts receivable, net arose from product sales in the United States. For the six-month period ended June 30, 2023, 96% of sales were from three major wholesalers accounting for approximately 37%, 30%, and 29% of product sales. The percentage of the total net product sales by individual customers has not significantly changed since inception. All customers have standard payment terms which generally require payment within 60 days. As of June 30, 2023, the Company continues to believe that such customers are of high credit quality.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Investment Securities
 6 Months Ended
Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Investment Securities Investment Securities
Investment securities consisted of the following (in thousands):
June 30, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$219,575 $3 $(1,203)$218,375 
FDIC Certificates of Deposit5,132 — (58)5,074 
Certificates of Deposit65,000 — — 65,000 
Commercial Paper74,541 — (207)74,334 
Corporate Notes/Bonds88,553 1 (804)87,750 
$452,801 $4 $(2,272)$450,533 
December 31, 2022
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$188,465 $14 $(1,729)$186,750 
FDIC Certificates of Deposit4,155 3 (72)4,086 
Certificates of Deposit7,500 — — 7,500 
Commercial Paper100,711 3 (269)100,445 
Corporate Notes/Bonds189,588 1 (2,141)187,448 
$490,419 $21 $(4,211)$486,229 
The Company has classified all of its investment securities as available-for-sale, including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of June 30, 2023 and December 31, 2022, the Company held $25.5 million and $71.5 million, respectively, of available-for-sale investment securities with contractual maturity dates more than one year and less than two years, with the remainder of the available-for-sale investment securities having contractual maturity dates less than one year.
Unrealized losses as of June 30, 2023 approximate 1% of the estimated fair value of investments. The aggregate related fair value of investments with unrealized losses as of June 30, 2023 was $355.4 million, which consisted of $194.5 million from U.S. government agency securities, $5.1 million of certificates of deposit, $74.3 million of commercial paper, and $81.5 million of corporate notes/bonds. $83.8 million of the aggregate fair value of investments with unrealized losses as of June 30, 2023 has been held in a continuous unrealized loss position for over 12 months, with the remaining $271.6 million held in a continuous unrealized loss position for less than 12 months. As of December 31, 2022, the aggregate related fair value of investments with unrealized losses was $438.3 million. $49.1 million of the aggregate fair value of investments with unrealized losses as of December 31, 2022 had been held in a continuous unrealized loss position for over than 12 months, with the remaining $389.2 million held in a continuous unrealized loss position for less than 12 months. The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements
 6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company applies the fair value method under ASC Topic 820, Fair Value Measurements and Disclosures. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:
•Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
•Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
•Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.
The Company has no assets or liabilities that were measured using prices with significant unobservable inputs (Level 3 assets and liabilities) as of June 30, 2023 and December 31, 2022. The carrying value of cash held in money market funds of $5.3 million as of June 30, 2023 and $12.2 million as of December 31, 2022 is included in cash and cash equivalents on the condensed consolidated balance sheets and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in commercial paper of $5.0 million, U.S. government agency securities of $10.0 million and certificates of deposit of $65.0 million as of June 30, 2023 is included in cash and cash equivalents. The carrying value of cash held in commercial paper of $14.9 million, U.S. government agency securities of $20.5 million and certificates of deposit of $7.5 million as of December 31, 2022 is included in cash and cash equivalents.
The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):
Fair Value Measurements at
Reporting Date Using
June 30,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$5,319 $5,319 $— $— 
U.S. Government Agency Securities218,375 — 218,375 — 
FDIC Certificates of Deposit5,074 — 5,074 — 
Certificates of Deposit65,000 — 65,000 — 
Commercial Paper74,334 — 74,334 — 
Corporate Notes/Bonds87,750 — 87,750 — 
$455,852 $5,319 $450,533 $— 
Fair Value Measurements at
Reporting Date Using
December 31,
2022		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$12,203 $12,203 $— $— 
U.S. Government Agency Securities186,750 — 186,750 — 
FDIC Certificates of Deposit4,086 — 4,086 — 
Certificates of Deposit7,500 — 7,500 — 
Commercial Paper100,445 — 100,445 — 
Corporate Notes/Bonds187,448 — 187,448 — 
$498,432 $12,203 $486,229 $— 
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Inventory
 6 Months Ended
Jun. 30, 2023
Inventory Disclosure [Abstract]  
Inventory Inventory
Inventory consists of the following (in thousands):
June 30,
2023		December 31,
2022
Raw materials$33,901 $17,227 
Work in process4,051 2,594 
Finished goods3,943 4,099 
$41,895 $23,920 
The raw materials balance includes the active pharmaceutical ingredients (API) and any related intermediate compounds, which, supply exceeds 12 months of production needs.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Right of Use Assets and Lease Liabilities
 6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
Right of Use Assets and Lease Liabilities Right of Use Assets and Lease Liabilities
In 2014, the Company entered into a long-term lease with a related party, which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium-related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029.
The Company has also entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to obtain motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The contractual period of each lease is 12 months, followed by month-to-month renewal periods. The Company estimates the lease term for each vehicle to be 12 months. Leases which the Company determined to have a lease term of 12 months or less will be treated as short-term in accordance with the accounting policy election and are not recognized on the balance sheet. Each lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.75 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease, which has been recorded as restricted cash on the condensed consolidated balance sheets.
The Company has no other significant leases. In addition, no identified leases require allocations between lease and non-lease components.
The following tables present the lease balances within the condensed consolidated balance sheets, weighted average remaining lease term, and the weighted average discount rates related to leases as of June 30, 2023 and December 31, 2022 and operating cash outflows as of June 30, 2023 and 2022 (in thousands, except years and percentages):
June 30, 2023December 31, 2022
Other information
Weighted average remaining lease term5.8 years5.9 years
Weighted average discount rate9.07 %8.76 %
Six Months Ended June 30,
20232022
Lease cost
Operating lease cost$2,003$2,843
Variable lease cost724806
Short-term lease cost599—
$3,326$3,649
Maturity analyses under the lease agreements are as follows (in thousands):
Six months ending December 31, 2023$1,848 
Year ending December 31, 20243,792 
Year ending December 31, 20253,907 
Year ending December 31, 20263,974 
Year ending December 31, 20274,022 
Thereafter5,915 
Total23,458 
Less: Present value discount(5,468)
Total operating lease liability17,990 
Less: Current portion(3,558)
Operating lease liabilities, non-current$14,432 
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
License and Royalty Commitments
On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and know-how of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds.
Under the agreement, the Company has made payments of $10.75 million to BMS related to milestones achieved to date for lumateperone. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of non-royalty payments made in consideration of any sublicense.
The agreement extends, and royalties are payable, on a country-by-country and product-by-product basis, through the later of ten years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.
Purchase Commitments
The Company enters into certain other long-term commitments for goods and services that are outstanding for periods greater than one year. The Company recently amended certain manufacturing service agreements committing the Company to certain minimum annual purchase commitments for which the Company anticipates making payments within the years 2025 through 2029. As of June 30, 2023, the Company has committed to purchasing production campaigns for various raw materials including active pharmaceutical ingredients (API) and its intermediates from each of its supply vendors. The current campaigns are expected to be received into inventory during 2023 and 2024. The Company has paid deposits of $19.4 million and $21.6 million as of June 30, 2023 and December 31, 2022, respectively, for the various campaigns, which are recorded within prepaid expenses and other current assets. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan within the executed agreements.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Share-Based Compensation
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs) granted to employees and directors recognized during the six-month periods ended June 30, 2023 and 2022, was comprised of the following (in thousands):
Six Months Ended June 30,
20232022
Inventoriable costs$762 $824 
Selling, general and administrative15,705 12,224 
Research and development7,198 7,055 
Total share-based compensation expense$23,665 $20,103 
Information regarding the stock options activity, including with respect to grants to employees and directors as of June 30, 2023, and changes during the six-month period then ended, are summarized as follows:
Number of
Shares		Weighted-
Average
Exercise
Price		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20224,785,972$26.27 5.8 years
Options granted 2023275,420
Options exercised 2023(510,274)
Options canceled or expired 2023(35,930)
Outstanding at June 30, 20234,515,188$27.62 
Vested and expected to vest at June 30, 20234,515,188$27.62 
Exercisable at June 30, 20233,739,052$23.18 
The fair value of the time-based RSUs is based on the closing price of the Company’s common stock on the date of grant. Information regarding the time-based RSU activity and changes during the six-month period ended June 30, 2023 is summarized as follows:
Number of
Shares		Weighted-Average
Grant Date
Fair Value Per Share		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20221,274,664$42.76 0.8 years
Time-based RSUs granted in 20231,056,867
Time-based RSUs vested in 2023(655,204)
Time-based RSUs cancelled in 2023(50,056)
Outstanding at June 30, 20231,626,271$48.62 
As of June 30, 2023, there was approximately $68.5 million of unrecognized compensation costs estimated related to unvested time-based RSUs.
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Loss Per Share
 6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Loss Per Share Loss Per Share
The following share-based awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and six-month periods ended June 30, 2023 and 2022:
Three and Six Months Ended
June 30,
20232022
Stock options4,515,1885,241,804
RSUs1,841,8551,517,820
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Pay vs Performance Disclosure            
Net loss $ (42,784) $ (44,053) $ (86,603) $ (72,119) $ (86,837) $ (158,722)
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Insider Trading Arrangements
 3 Months Ended 6 Months Ended
Jun. 30, 2023
shares
Jun. 30, 2023
shares
Trading Arrangements, by Individual    
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Michael I. Halstead [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   •On May 8, 2023, Michael I. Halstead, Executive Vice President, General Counsel and Secretary, modified his Rule 10b5-1 Trading Plan, originally adopted on March 15, 2023, to change the start date of the plan to January 2, 2024, and reduce the number of shares to be sold under the plan. The modified plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 37,872 shares of our common stock until March 28, 2024.
Name Michael I. Halstead  
Title Executive Vice President, General Counsel and Secretary,  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date May 8, 2023  
Arrangement Duration 86 days  
Aggregate Available 37,872 37,872
Sharon Mates [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   On June 9, 2023, Sharon Mates, Ph.D., Chairman, President and Chief Executive Officer, modified her Rule 10b5-1 Trading Plan, originally adopted on March 14, 2023, to change the start date to September 18, 2023 and the end date of the plan to May 31, 2024, and reduce the number of shares to be sold under the plan. The modified plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 402,337 shares of our common stock including the potential sale of up to 191,362 shares of our common stock upon the exercise of stock options with an exercise expiration date of June 30, 2024. Furthermore, we expect a significant portion of the proceeds from any sales under the plan will be used to cover Dr. Mates' tax liability arising from such sales.
Name Sharon Mates  
Title Chairman, President and Chief Executive Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date June 9, 2023  
Arrangement Duration 256 days  
Aggregate Available 402,337 402,337
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders.
Recent Accounting Pronouncements Recent Accounting Pronouncements Management has evaluated all accounting pronouncements issued through the date of the condensed consolidated financial statements and does not believe that any recently issued, but not yet effective, pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.
Use of Estimates Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Significant Accounting Policies Significant Accounting Policies The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Concentration of Credit Risk Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. As of June 30, 2023, the majority of the Company’s accounts receivable, net arose from product sales in the United States. For the six-month period ended June 30, 2023, 96% of sales were from three major wholesalers accounting for approximately 37%, 30%, and 29% of product sales. The percentage of the total net product sales by individual customers has not significantly changed since inception. All customers have standard payment terms which generally require payment within 60 days. As of June 30, 2023, the Company continues to believe that such customers are of high credit quality.
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Investment Securities (Tables)
 6 Months Ended
Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Schedule of Investment Securities
Investment securities consisted of the following (in thousands):
June 30, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$219,575 $3 $(1,203)$218,375 
FDIC Certificates of Deposit5,132 — (58)5,074 
Certificates of Deposit65,000 — — 65,000 
Commercial Paper74,541 — (207)74,334 
Corporate Notes/Bonds88,553 1 (804)87,750 
$452,801 $4 $(2,272)$450,533 
December 31, 2022
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$188,465 $14 $(1,729)$186,750 
FDIC Certificates of Deposit4,155 3 (72)4,086 
Certificates of Deposit7,500 — — 7,500 
Commercial Paper100,711 3 (269)100,445 
Corporate Notes/Bonds189,588 1 (2,141)187,448 
$490,419 $21 $(4,211)$486,229 
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities
The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):
Fair Value Measurements at
Reporting Date Using
June 30,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$5,319 $5,319 $— $— 
U.S. Government Agency Securities218,375 — 218,375 — 
FDIC Certificates of Deposit5,074 — 5,074 — 
Certificates of Deposit65,000 — 65,000 — 
Commercial Paper74,334 — 74,334 — 
Corporate Notes/Bonds87,750 — 87,750 — 
$455,852 $5,319 $450,533 $— 
Fair Value Measurements at
Reporting Date Using
December 31,
2022		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$12,203 $12,203 $— $— 
U.S. Government Agency Securities186,750 — 186,750 — 
FDIC Certificates of Deposit4,086 — 4,086 — 
Certificates of Deposit7,500 — 7,500 — 
Commercial Paper100,445 — 100,445 — 
Corporate Notes/Bonds187,448 — 187,448 — 
$498,432 $12,203 $486,229 $— 
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Inventory (Tables)
 6 Months Ended
Jun. 30, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current
Inventory consists of the following (in thousands):
June 30,
2023		December 31,
2022
Raw materials$33,901 $17,227 
Work in process4,051 2,594 
Finished goods3,943 4,099 
$41,895 $23,920 
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Right of Use Assets and Lease Liabilities (Tables)
 6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
Schedule of Quantitative Information About Operating Leases
The following tables present the lease balances within the condensed consolidated balance sheets, weighted average remaining lease term, and the weighted average discount rates related to leases as of June 30, 2023 and December 31, 2022 and operating cash outflows as of June 30, 2023 and 2022 (in thousands, except years and percentages):
June 30, 2023December 31, 2022
Other information
Weighted average remaining lease term5.8 years5.9 years
Weighted average discount rate9.07 %8.76 %
Six Months Ended June 30,
20232022
Lease cost
Operating lease cost$2,003$2,843
Variable lease cost724806
Short-term lease cost599—
$3,326$3,649
Schedule Of Maturity Analysis Under Lease Agreements
Maturity analyses under the lease agreements are as follows (in thousands):
Six months ending December 31, 2023$1,848 
Year ending December 31, 20243,792 
Year ending December 31, 20253,907 
Year ending December 31, 20263,974 
Year ending December 31, 20274,022 
Thereafter5,915 
Total23,458 
Less: Present value discount(5,468)
Total operating lease liability17,990 
Less: Current portion(3,558)
Operating lease liabilities, non-current$14,432 
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Share-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Share-Based Payment Arrangement, Expensed and Capitalized, Amount
Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs) granted to employees and directors recognized during the six-month periods ended June 30, 2023 and 2022, was comprised of the following (in thousands):
Six Months Ended June 30,
20232022
Inventoriable costs$762 $824 
Selling, general and administrative15,705 12,224 
Research and development7,198 7,055 
Total share-based compensation expense$23,665 $20,103 
Stock Option Activity
Information regarding the stock options activity, including with respect to grants to employees and directors as of June 30, 2023, and changes during the six-month period then ended, are summarized as follows:
Number of
Shares		Weighted-
Average
Exercise
Price		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20224,785,972$26.27 5.8 years
Options granted 2023275,420
Options exercised 2023(510,274)
Options canceled or expired 2023(35,930)
Outstanding at June 30, 20234,515,188$27.62 
Vested and expected to vest at June 30, 20234,515,188$27.62 
Exercisable at June 30, 20233,739,052$23.18 
Summary of Information Regarding RSU Activity Information regarding the time-based RSU activity and changes during the six-month period ended June 30, 2023 is summarized as follows:
Number of
Shares		Weighted-Average
Grant Date
Fair Value Per Share		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20221,274,664$42.76 0.8 years
Time-based RSUs granted in 20231,056,867
Time-based RSUs vested in 2023(655,204)
Time-based RSUs cancelled in 2023(50,056)
Outstanding at June 30, 20231,626,271$48.62 
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Loss Per Share - (Tables)
 6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share
The following share-based awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and six-month periods ended June 30, 2023 and 2022:
Three and Six Months Ended
June 30,
20232022
Stock options4,515,1885,241,804
RSUs1,841,8551,517,820
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Additional Information (Detail)
 6 Months Ended
Jun. 30, 2023
Segment
Significant Accounting Policies [Line Items]  
Number of operating segments 1
Revenue Benchmark | Customer Concentration Risk | Three Major Wholesalers  
Significant Accounting Policies [Line Items]  
Concentration risk (as a percent) 96.00%
Revenue Benchmark | Customer Concentration Risk | Customer One  
Significant Accounting Policies [Line Items]  
Concentration risk (as a percent) 37.00%
Revenue Benchmark | Customer Concentration Risk | Customer Two  
Significant Accounting Policies [Line Items]  
Concentration risk (as a percent) 30.00%
Revenue Benchmark | Customer Concentration Risk | Customer Three  
Significant Accounting Policies [Line Items]  
Concentration risk (as a percent) 29.00%
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Investment Securities - Summary of Investment Securities (Detail) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost $ 452,801 $ 490,419
Unrealized Gains 4 21
Unrealized (Losses) (2,272) (4,211)
Estimated Fair Value 450,533 486,229
U.S. Government Agency Securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 219,575 188,465
Unrealized Gains 3 14
Unrealized (Losses) (1,203) (1,729)
Estimated Fair Value 218,375 186,750
FDIC Certificates of Deposit    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 5,132 4,155
Unrealized Gains 0 3
Unrealized (Losses) (58) (72)
Estimated Fair Value 5,074 4,086
Certificates of Deposit    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 65,000 7,500
Unrealized Gains 0 0
Unrealized (Losses) 0 0
Estimated Fair Value 65,000 7,500
Commercial Paper    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 74,541 100,711
Unrealized Gains 0 3
Unrealized (Losses) (207) (269)
Estimated Fair Value 74,334 100,445
Corporate Notes/Bonds    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 88,553 189,588
Unrealized Gains 1 1
Unrealized (Losses) (804) (2,141)
Estimated Fair Value $ 87,750 $ 187,448
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Investment Securities - Additional Information (Detail)
$ in Millions
Jun. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Debt Securities, Available-for-Sale [Line Items]    
Investment securities, available for sale, noncurrent $ 25.5 $ 71.5
Percentage of fair value instruments (0.01)  
Aggregate related fair value of investments with unrealized losses $ 355.4 438.3
Aggregate fair value of investments with unrealized losses 83.8 49.1
Continuous unrealized losses, value remaining 271.6 $ 389.2
U.S. Government Agency Securities    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses 194.5  
Certificates of Deposit    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses 5.1  
Commercial Paper    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses 74.3  
Corporate Notes/Bonds    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses $ 81.5  
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Additional Information (Detail) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Carrying value of cash held in money market funds $ 5.3 $ 12.2
Cash and Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Commercial paper value listed as cash equivalent 5.0 14.9
Carrying value of cash held in commercial paper, government securities 10.0 20.5
Certificates of deposits 65.0 7.5
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities measured using quoted prices 0.0 0.0
Assets measured using quoted prices $ 0.0 $ 0.0
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities $ 455,852 $ 498,432
Fair Value, Measurements, Recurring | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 5,319 12,203
Fair Value, Measurements, Recurring | U.S. Government Agency Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 218,375 186,750
Fair Value, Measurements, Recurring | FDIC Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 5,074 4,086
Fair Value, Measurements, Recurring | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 65,000 7,500
Fair Value, Measurements, Recurring | Commercial Paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 74,334 100,445
Fair Value, Measurements, Recurring | Corporate Notes/Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 87,750 187,448
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 5,319 12,203
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 5,319 12,203
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | U.S. Government Agency Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | FDIC Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | Commercial Paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | Corporate Notes/Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 450,533 486,229
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | U.S. Government Agency Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 218,375 186,750
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | FDIC Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 5,074 4,086
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 65,000 7,500
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Commercial Paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 74,334 100,445
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate Notes/Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 87,750 187,448
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | U.S. Government Agency Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | FDIC Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Commercial Paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate Notes/Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities $ 0 $ 0
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Inventory - Schedule of Inventory, Current (Detail) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 33,901 $ 17,227
Work in process 4,051 2,594
Finished goods 3,943 4,099
Total inventories $ 41,895 $ 23,920
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Right of Use Assets and Lease Liabilities - Additional Information (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Sep. 30, 2018
Vehicle Lease    
Operating Leased Assets [Line Items]    
Term of long term lease 12 months  
Guarantor obligations, value $ 1,750  
NEW YORK    
Operating Leased Assets [Line Items]    
Term of long term lease   14 years 3 months 18 days
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Other information      
Weighted average remaining lease term (in years) 5 years 9 months 18 days   5 years 10 months 24 days
Weighted average discount rate (as a percent) 9.07%   8.76%
Lease cost      
Operating lease cost $ 2,003 $ 2,843  
Variable lease cost 724 806  
Short-term lease cost 599 0  
Total lease cost $ 3,326 $ 3,649  
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Leases [Abstract]    
Six months ending December 31, 2023 $ 1,848  
Year ending December 31, 2024 3,792  
Year ending December 31, 2025 3,907  
Year ending December 31, 2026 3,974  
Year ending December 31, 2027 4,022  
Thereafter 5,915  
Total 23,458  
Less: Present value discount (5,468)  
Total operating lease liability 17,990  
Less: Current portion (3,558) $ (4,567)
Operating lease liabilities, non-current $ 14,432 $ 15,474
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
 6 Months Ended 217 Months Ended
May 31, 2005
Jun. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Purchase Commitment        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Cash paid   $ 19,400 $ 19,400 $ 21,600
Product | Bristol-Myers Squibb Company        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Company made an upfront payment     10,750  
Payment of milestone amount   $ 5,000 $ 5,000  
Obliged to make milestone payments $ 14,750      
License expiration period   10 years    
Product | Bristol-Myers Squibb Company | Minimum        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Royalty payment, percentage (as a percent) 5.00%      
Product | Bristol-Myers Squibb Company | Maximum        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Royalty payment, percentage (as a percent) 9.00%      
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Total share-based compensation expense $ 23,665 $ 20,103
Inventoriable costs    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Total share-based compensation expense 762 824
Selling, general and administrative    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Total share-based compensation expense 15,705 12,224
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Total share-based compensation expense $ 7,198 $ 7,055
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Share-Based Compensation - Stock Options Activity (Detail) - $ / shares
 6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]    
Outstanding at beginning of period, Number of Shares (in shares) 4,785,972  
Options granted, Number of Shares (in shares) 275,420  
Options exercised, Number of Shares (in shares) (510,274)  
Options canceled or expired, Number of Shares (in shares) (35,930)  
Outstanding at end of period, Number of Shares (in shares) 4,515,188 4,785,972
Vested or expected to vest at end of period, Number of Shares (in shares) 4,515,188  
Exercisable at end of period, Number of Shares (in shares) 3,739,052  
Weighted- Average Exercise Price    
Outstanding at beginning of period, Weighted-Average Exercise Price (in dollars per share) $ 26.27  
Outstanding at end of period, Weighted-Average Exercise Price (in dollars per share) 27.62 $ 26.27
Vested or expected to vest at end of period, Weighted-Average Exercise Price (in dollars per share) 27.62  
Exercisable at end of period, Weighted-Average Exercise Price (in dollars per share) $ 23.18  
Outstanding at end of period, Weighted-Average Contractual Life (in years)   5 years 9 months 18 days
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) - RSUs - $ / shares
 6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward]    
Outstanding at beginning of year, Number of Shares (in shares) 1,274,664  
Time based RSU's granted, Number of Shares (in shares) 1,056,867  
Time based RSU's vested, Number of Shares (in shares) (655,204)  
Time based RSU's cancelled, Number of Shares (in shares) (50,056)  
Outstanding at end of year, Number of Shares (in shares) 1,626,271 1,274,664
Weighted-Average Grant Date Fair Value Per Share    
Outstanding at beginning of year, Weighted-Average Grant Date Fair Value (in dollars per share) $ 42.76  
Time based RSU's granted, Weighted-Average Grant Date Fair Value (in dollars per share)  
Time based RSU's vested, Weighted-Average Grant Date Fair Value (in dollars per share)  
Time based RSU's cancelled, Weighted-Average Grant Date Fair Value (in dollars per share)  
Outstanding at end of year, Weighted-Average Grant Date Fair Value (in dollars per share) $ 48.62 $ 42.76
Restricted stock outstanding, Weighted-Average Contractual Life (in years) 9 months 18 days
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Share-Based Compensation - Additional Information (Detail)
$ in Millions
Jun. 30, 2023
USD ($)
Time Based Restricted Stock Units  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation costs related to unvested RSUs $ 68.5
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) - shares
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Number of anti-dilutive securities excluded from computation of earnings per share (in shares) 4,515,188 5,241,804 4,515,188 5,241,804
RSUs        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Number of anti-dilutive securities excluded from computation of earnings per share (in shares) 1,841,855 1,517,820 1,841,855 1,517,820
XML 51 itci-20230630_htm.xml IDEA: XBRL DOCUMENT 0001567514 2023-01-01 2023-06-30 0001567514 2023-08-01 0001567514 2023-06-30 0001567514 2022-12-31 0001567514 us-gaap:ProductMember 2023-04-01 2023-06-30 0001567514 us-gaap:ProductMember 2022-04-01 2022-06-30 0001567514 us-gaap:ProductMember 2023-01-01 2023-06-30 0001567514 us-gaap:ProductMember 2022-01-01 2022-06-30 0001567514 us-gaap:GrantMember 2023-04-01 2023-06-30 0001567514 us-gaap:GrantMember 2022-04-01 2022-06-30 0001567514 us-gaap:GrantMember 2023-01-01 2023-06-30 0001567514 us-gaap:GrantMember 2022-01-01 2022-06-30 0001567514 2023-04-01 2023-06-30 0001567514 2022-04-01 2022-06-30 0001567514 2022-01-01 2022-06-30 0001567514 us-gaap:CommonStockMember 2021-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001567514 us-gaap:RetainedEarningsMember 2021-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001567514 2021-12-31 0001567514 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001567514 2022-01-01 2022-03-31 0001567514 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001567514 us-gaap:CommonStockMember 2022-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001567514 us-gaap:RetainedEarningsMember 2022-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001567514 2022-03-31 0001567514 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001567514 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001567514 us-gaap:CommonStockMember 2022-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001567514 us-gaap:RetainedEarningsMember 2022-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001567514 2022-06-30 0001567514 us-gaap:CommonStockMember 2022-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001567514 us-gaap:RetainedEarningsMember 2022-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001567514 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001567514 2023-01-01 2023-03-31 0001567514 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001567514 us-gaap:CommonStockMember 2023-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001567514 us-gaap:RetainedEarningsMember 2023-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001567514 2023-03-31 0001567514 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001567514 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001567514 us-gaap:CommonStockMember 2023-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001567514 us-gaap:RetainedEarningsMember 2023-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001567514 itci:ThreeMajorWholesalersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001567514 itci:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001567514 itci:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001567514 itci:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001567514 itci:FDICCertificatesOfDepositMember 2023-06-30 0001567514 us-gaap:CertificatesOfDepositMember 2023-06-30 0001567514 us-gaap:CommercialPaperMember 2023-06-30 0001567514 us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001567514 itci:FDICCertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:CertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:CommercialPaperMember 2022-12-31 0001567514 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001567514 us-gaap:CashAndCashEquivalentsMember 2023-06-30 0001567514 us-gaap:CashAndCashEquivalentsMember 2022-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-06-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-06-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-06-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-06-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001567514 stpr:NY 2018-09-30 0001567514 us-gaap:VehiclesMember 2023-06-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2005-05-31 2023-06-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2023-06-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2005-05-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember srt:MinimumMember 2005-05-31 2005-05-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember srt:MaximumMember 2005-05-31 2005-05-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2023-01-01 2023-06-30 0001567514 us-gaap:PurchaseCommitmentMember 2023-06-30 0001567514 us-gaap:PurchaseCommitmentMember 2022-12-31 0001567514 itci:InventoriableCostsMember 2023-01-01 2023-06-30 0001567514 itci:InventoriableCostsMember 2022-01-01 2022-06-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-06-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001567514 2022-01-01 2022-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2023-06-30 0001567514 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001567514 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001567514 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001567514 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001567514 itci:MichaelIHalsteadMember 2023-01-01 2023-06-30 0001567514 itci:MichaelIHalsteadMember 2023-04-01 2023-06-30 0001567514 itci:MichaelIHalsteadMember 2023-06-30 0001567514 itci:SharonMatesMember 2023-01-01 2023-06-30 0001567514 itci:SharonMatesMember 2023-04-01 2023-06-30 0001567514 itci:SharonMatesMember 2023-06-30 shares iso4217:USD iso4217:USD shares itci:Segment pure 0001567514 --12-31 2023 Q2 false P86D P256D 10-Q true 2023-06-30 false 001-36274 INTRA-CELLULAR THERAPIES, INC. DE 36-4742850 430 East 29th Street New York NY 10016 646 440-9333 Common Stock ITCI NASDAQ Yes Yes Large Accelerated Filer false false false 96091564 142258000 148615000 370596000 443290000 1750000 1750000 95964000 75189000 41895000 23920000 45610000 45193000 698073000 737957000 1656000 1913000 13787000 14824000 86000 86000 713602000 754780000 7733000 10395000 27456000 19657000 31710000 25621000 21623000 22996000 3558000 4567000 92080000 83236000 14432000 15474000 106512000 98710000 0.0001 0.0001 175000000 175000000 96083387 96083387 94829794 94829794 10000 9000 2173671000 2137737000 -1564323000 -1477486000 -2268000 -4190000 607090000 656070000 713602000 754780000 110128000 55074000 204859000 89829000 664000 505000 1239000 746000 110792000 55579000 206098000 90575000 7163000 4650000 13914000 7805000 101014000 100316000 199937000 175776000 49794000 38536000 87818000 67579000 157971000 143502000 301669000 251160000 -47179000 -87923000 -95571000 -160585000 4530000 1320000 8879000 1868000 -42649000 -86603000 -86692000 -158717000 135000 0 145000 5000 -42784000 -86603000 -86837000 -158722000 -0.45 -0.45 -0.92 -0.92 -0.91 -0.91 -1.70 -1.70 95948063 95948063 94285117 94285117 95543626 95543626 93449424 93449424 -42784000 -86603000 -86837000 -158722000 430000 -1474000 1922000 -4438000 -42354000 -88077000 -84915000 -163160000 81886965 8000 1639476000 -1221230000 -364000 417890000 10952381 1000 433724000 433725000 1180696 8089000 8089000 383 24000 24000 8105000 8105000 -72119000 -72119000 -2964000 -2964000 94020425 9000 2089418000 -1293349000 -3328000 792750000 346411 5504000 5504000 397 22000 22000 11998000 11998000 -86603000 -86603000 -1474000 -1474000 94367233 9000 2106942000 -1379952000 -4802000 722197000 94829794 9000 2137737000 -1477486000 -4190000 656070000 849827 1000 3639000 3640000 408 22000 22000 10439000 10439000 -44053000 -44053000 1492000 1492000 95680029 10000 2151837000 -1521539000 -2698000 627610000 402994 8585000 8585000 364 23000 23000 13226000 13226000 -42784000 -42784000 430000 430000 96083387 10000 2173671000 -1564323000 -2268000 607090000 -86837000 -158722000 257000 343000 23665000 20103000 45000 46000 3670000 947000 20775000 26820000 17975000 17074000 417000 12535000 -2662000 2058000 7799000 6201000 -6089000 -10519000 -1373000 -2512000 -1014000 1698000 -96868000 -177642000 174411000 552782000 252697000 268665000 0 689000 78286000 -284806000 0 433725000 12225000 13593000 12225000 447318000 -6357000 -15130000 150365000 93765000 144008000 78635000 0 4167000 142258000 77235000 1750000 1400000 144008000 78635000 Organization Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiary, ITI, Inc. (“ITI”), is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (“CNS”). In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42mg/day) and the Company initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42mg/day). The Company initiated the commercial launch of CAPLYTA for the treatment of bipolar depression in December 2021. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). The commercial launch of these special population doses occurred in August 2022. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression. Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder. In order to further its commercial activities and research projects and support its collaborations, the Company may require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt or convertible debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s products, product candidates and technology and, to a much lesser extent, grant funding. Summary of Significant Accounting Policies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated all accounting pronouncements issued through the date of the condensed consolidated financial statements and does not believe that any recently issued, but not yet effective, pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div>Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. As of June 30, 2023, the majority of the Company’s accounts receivable, net arose from product sales in the United States. For the six-month period ended June 30, 2023, 96% of sales were from three major wholesalers accounting for approximately 37%, 30%, and 29% of product sales. The percentage of the total net product sales by individual customers has not significantly changed since inception. All customers have standard payment terms which generally require payment within 60 days. As of June 30, 2023, the Company continues to believe that such customers are of high credit quality. Basis of Presentation The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders. 1 1 Recent Accounting Pronouncements Management has evaluated all accounting pronouncements issued through the date of the condensed consolidated financial statements and does not believe that any recently issued, but not yet effective, pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. Significant Accounting Policies The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. As of June 30, 2023, the majority of the Company’s accounts receivable, net arose from product sales in the United States. For the six-month period ended June 30, 2023, 96% of sales were from three major wholesalers accounting for approximately 37%, 30%, and 29% of product sales. The percentage of the total net product sales by individual customers has not significantly changed since inception. All customers have standard payment terms which generally require payment within 60 days. As of June 30, 2023, the Company continues to believe that such customers are of high credit quality. 0.96 0.37 0.30 0.29 Investment Securities <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">219,575</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,203)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">218,375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">65,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">65,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">74,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">74,334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">88,553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">452,801</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,272)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">450,533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188,465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,729)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490,419 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,211)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,229 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified all of its investment securities as available-for-sale, including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of June 30, 2023 and December 31, 2022, the Company held $25.5 million and $71.5 million, respectively, of available-for-sale investment securities with contractual maturity dates more than one year and less than two years, with the remainder of the available-for-sale investment securities having contractual maturity dates less than one year. </span></div>Unrealized losses as of June 30, 2023 approximate 1% of the estimated fair value of investments. The aggregate related fair value of investments with unrealized losses as of June 30, 2023 was $355.4 million, which consisted of $194.5 million from U.S. government agency securities, $5.1 million of certificates of deposit, $74.3 million of commercial paper, and $81.5 million of corporate notes/bonds. $83.8 million of the aggregate fair value of investments with unrealized losses as of June 30, 2023 has been held in a continuous unrealized loss position for over 12 months, with the remaining $271.6 million held in a continuous unrealized loss position for less than 12 months. As of December 31, 2022, the aggregate related fair value of investments with unrealized losses was $438.3 million. $49.1 million of the aggregate fair value of investments with unrealized losses as of December 31, 2022 had been held in a continuous unrealized loss position for over than 12 months, with the remaining $389.2 million held in a continuous unrealized loss position for less than 12 months. The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">219,575</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,203)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">218,375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">65,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">65,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">74,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">74,334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">88,553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">452,801</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,272)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">450,533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188,465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,729)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490,419 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,211)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,229 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 219575000 3000 1203000 218375000 5132000 0 58000 5074000 65000000 0 0 65000000 74541000 0 207000 74334000 88553000 1000 804000 87750000 452801000 4000 2272000 450533000 188465000 14000 1729000 186750000 4155000 3000 72000 4086000 7500000 0 0 7500000 100711000 3000 269000 100445000 189588000 1000 2141000 187448000 490419000 21000 4211000 486229000 25500000 71500000 0.01 355400000 194500000 5100000 74300000 81500000 83800000 271600000 438300000 49100000 389200000 Fair Value Measurements <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value method under ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no assets or liabilities that were measured using prices with significant unobservable inputs (Level 3 assets and liabilities) as of June 30, 2023 and December 31, 2022. The carrying value of cash held in money market funds of $5.3 million as of June 30, 2023 and $12.2 million as of December 31, 2022 is included in cash and cash equivalents on the condensed consolidated balance sheets and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in commercial paper of $5.0 million, U.S. government agency securities of $10.0 million and certificates of deposit of $65.0 million as of June 30, 2023 is included in cash and cash equivalents. The carrying value of cash held in commercial paper of $14.9 million, U.S. government agency securities of $20.5 million and certificates of deposit of $7.5 million as of December 31, 2022 is included in cash and cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">218,375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">218,375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">65,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">65,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">74,334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">74,334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">455,852</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">450,533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,203 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,203 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">498,432 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,203 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,229 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 0 5300000 12200000 5000000 10000000 65000000 14900000 20500000 7500000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">218,375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">218,375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">65,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">65,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">74,334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">74,334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">455,852</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">450,533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,203 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,203 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">498,432 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,203 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,229 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5319000 5319000 0 0 218375000 0 218375000 0 5074000 0 5074000 0 65000000 0 65000000 0 74334000 0 74334000 0 87750000 0 87750000 0 455852000 5319000 450533000 0 12203000 12203000 0 0 186750000 0 186750000 0 4086000 0 4086000 0 7500000 0 7500000 0 100445000 0 100445000 0 187448000 0 187448000 0 498432000 12203000 486229000 0 Inventory <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">33,901</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,051</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,943</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">41,895</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,920 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The raw materials balance includes the active pharmaceutical ingredients (API) and any related intermediate compounds, which, supply exceeds 12 months of production needs.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">33,901</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,051</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,943</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">41,895</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,920 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 33901000 17227000 4051000 2594000 3943000 4099000 41895000 23920000 Right of Use Assets and Lease Liabilities <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the Company entered into a long-term lease with a related party, which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium-related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to obtain motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The contractual period of each lease is 12 months, followed by month-to-month renewal periods. The Company estimates the lease term for each vehicle to be 12 months. Leases which the Company determined to have a lease term of 12 months or less will be treated as short-term in accordance with the accounting policy election and are not recognized on the balance sheet. Each lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.75 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease, which has been recorded as restricted cash on the condensed consolidated balance sheets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no other significant leases. In addition, no identified leases require allocations between lease and non-lease components. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the lease balances within the condensed consolidated balance sheets, weighted average remaining lease term, and the weighted average discount rates related to leases as of June 30, 2023 and December 31, 2022 and operating cash outflows as of June 30, 2023 and 2022 (in thousands, except years and percentages): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.8 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.07</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,003</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,843</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">724</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">806</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">599</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,326</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,649</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity analyses under the lease agreements are as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six months ending December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,848 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,458 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Present value discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,558)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,432 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P14Y3M18D P12M P12M 1750000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the lease balances within the condensed consolidated balance sheets, weighted average remaining lease term, and the weighted average discount rates related to leases as of June 30, 2023 and December 31, 2022 and operating cash outflows as of June 30, 2023 and 2022 (in thousands, except years and percentages): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.8 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.07</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,003</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,843</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">724</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">806</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">599</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,326</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,649</span></td></tr></table></div> P5Y9M18D P5Y10M24D 0.0907 0.0876 2003000 2843000 724000 806000 599000 0 3326000 3649000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity analyses under the lease agreements are as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six months ending December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,848 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,458 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Present value discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,558)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,432 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1848000 3792000 3907000 3974000 4022000 5915000 23458000 5468000 17990000 3558000 14432000 Commitments and Contingencies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Royalty Commitments </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and know-how of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, the Company has made payments of $10.75 million to BMS related to milestones achieved to date for lumateperone. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of non-royalty payments made in consideration of any sublicense. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement extends, and royalties are payable, on a country-by-country and product-by-product basis, through the later of ten years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Commitments </span></div>The Company enters into certain other long-term commitments for goods and services that are outstanding for periods greater than one year. The Company recently amended certain manufacturing service agreements committing the Company to certain minimum annual purchase commitments for which the Company anticipates making payments within the years 2025 through 2029. As of June 30, 2023, the Company has committed to purchasing production campaigns for various raw materials including active pharmaceutical ingredients (API) and its intermediates from each of its supply vendors. The current campaigns are expected to be received into inventory during 2023 and 2024. The Company has paid deposits of $19.4 million and $21.6 million as of June 30, 2023 and December 31, 2022, respectively, for the various campaigns, which are recorded within prepaid expenses and other current assets. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan within the executed agreements. 10750000 5000000 14750000 0.05 0.09 P10Y 19400000 21600000 Share-Based Compensation <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs) granted to employees and directors recognized during the six-month periods ended June 30, 2023 and 2022, was comprised of the following (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventoriable costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">824 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15,705</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23,665</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,103 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the stock options activity, including with respect to grants to employees and directors as of June 30, 2023, and changes during the six-month period then ended, are summarized as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,785,972</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275,420</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(510,274)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35,930)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,515,188</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,515,188</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.62 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,739,052</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.18 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the time-based RSUs is based on the closing price of the Company’s common stock on the date of grant. Information regarding the time-based RSU activity and changes during the six-month period ended June 30, 2023 is summarized as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Grant Date<br/>Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,274,664</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs granted in 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,056,867</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs vested in 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(655,204)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs cancelled in 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50,056)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,626,271</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.62 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div>As of June 30, 2023, there was approximately $68.5 million of unrecognized compensation costs estimated related to unvested time-based RSUs. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs) granted to employees and directors recognized during the six-month periods ended June 30, 2023 and 2022, was comprised of the following (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventoriable costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">824 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15,705</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23,665</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,103 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 762000 824000 15705000 12224000 7198000 7055000 23665000 20103000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the stock options activity, including with respect to grants to employees and directors as of June 30, 2023, and changes during the six-month period then ended, are summarized as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,785,972</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275,420</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(510,274)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35,930)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,515,188</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,515,188</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.62 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,739,052</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.18 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 4785972 26.27 P5Y9M18D 275420 510274 35930 4515188 27.62 4515188 27.62 3739052 23.18 Information regarding the time-based RSU activity and changes during the six-month period ended June 30, 2023 is summarized as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Grant Date<br/>Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,274,664</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs granted in 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,056,867</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs vested in 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(655,204)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs cancelled in 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50,056)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,626,271</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.62 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table> 1274664 42.76 P0Y9M18D 1056867 655204 50056 1626271 48.62 68500000 Loss Per Share <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share-based awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and six-month periods ended June 30, 2023 and 2022: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three and Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,515,188</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,241,804</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,841,855</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,517,820</span></td></tr></table></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share-based awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and six-month periods ended June 30, 2023 and 2022: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three and Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,515,188</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,241,804</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,841,855</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,517,820</span></td></tr></table></div> 4515188 4515188 5241804 5241804 1841855 1841855 1517820 1517820 false <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">On May 8, 2023, Michael I. Halstead, Executive Vice President, General Counsel and Secretary, modified his Rule 10b5-1 Trading Plan, originally adopted on March 15, 2023, to change the start date of the plan to January 2, 2024, and reduce the number of shares to be sold under the plan. The modified plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 37,872 shares of our common stock until March 28, 2024.</span> May 8, 2023 Michael I. Halstead Executive Vice President, General Counsel and Secretary, true 37872 On June 9, 2023, Sharon Mates, Ph.D., Chairman, President and Chief Executive Officer, modified her Rule 10b5-1 Trading Plan, originally adopted on March 14, 2023, to change the start date to September 18, 2023 and the end date of the plan to May 31, 2024, and reduce the number of shares to be sold under the plan. The modified plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 402,337 shares of our common stock including the potential sale of up to 191,362 shares of our common stock upon the exercise of stock options with an exercise expiration date of June 30, 2024. Furthermore, we expect a significant portion of the proceeds from any sales under the plan will be used to cover Dr. Mates' tax liability arising from such sales. June 9, 2023 Sharon Mates Chairman, President and Chief Executive Officer true 402337 false false EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

>A66=H@, ,$; / M " ?;0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "# M/0-7*5V(H),! #B& &@ @ '%U >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "#/0-7B(RI-Z4! O&0 $P M @ &0U@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 ,0 Q + $X- !FV ! end XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 171 204 1 false 43 0 false 5 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.intracellulartherapies.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows (Parenthetical) Statements 8 false false R9.htm 0000009 - Disclosure - Organization Sheet http://www.intracellulartherapies.com/role/Organization Organization Notes 9 false false R10.htm 0000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Investment Securities Sheet http://www.intracellulartherapies.com/role/InvestmentSecurities Investment Securities Notes 11 false false R12.htm 0000012 - Disclosure - Fair Value Measurements Sheet http://www.intracellulartherapies.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 0000013 - Disclosure - Inventory Sheet http://www.intracellulartherapies.com/role/Inventory Inventory Notes 13 false false R14.htm 0000014 - Disclosure - Right of Use Assets and Lease Liabilities Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities Right of Use Assets and Lease Liabilities Notes 14 false false R15.htm 0000015 - Disclosure - Commitments and Contingencies Sheet http://www.intracellulartherapies.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 15 false false R16.htm 0000016 - Disclosure - Share-Based Compensation Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensation Share-Based Compensation Notes 16 false false R17.htm 0000017 - Disclosure - Loss Per Share Sheet http://www.intracellulartherapies.com/role/LossPerShare Loss Per Share Notes 17 false false R18.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 18 false false R19.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 19 false false R20.htm 9954701 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies 20 false false R21.htm 9954702 - Disclosure - Investment Securities (Tables) Sheet http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables Investment Securities (Tables) Tables http://www.intracellulartherapies.com/role/InvestmentSecurities 21 false false R22.htm 9954703 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.intracellulartherapies.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.intracellulartherapies.com/role/FairValueMeasurements 22 false false R23.htm 9954704 - Disclosure - Inventory (Tables) Sheet http://www.intracellulartherapies.com/role/InventoryTables Inventory (Tables) Tables http://www.intracellulartherapies.com/role/Inventory 23 false false R24.htm 9954705 - Disclosure - Right of Use Assets and Lease Liabilities (Tables) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables Right of Use Assets and Lease Liabilities (Tables) Tables http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities 24 false false R25.htm 9954706 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.intracellulartherapies.com/role/ShareBasedCompensation 25 false false R26.htm 9954707 - Disclosure - Loss Per Share - (Tables) Sheet http://www.intracellulartherapies.com/role/LossPerShareTables Loss Per Share - (Tables) Tables http://www.intracellulartherapies.com/role/LossPerShare 26 false false R27.htm 9954708 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 27 false false R28.htm 9954709 - Disclosure - Investment Securities - Summary of Investment Securities (Detail) Sheet http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail Investment Securities - Summary of Investment Securities (Detail) Details 28 false false R29.htm 9954710 - Disclosure - Investment Securities - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail Investment Securities - Additional Information (Detail) Details 29 false false R30.htm 9954711 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 30 false false R31.htm 9954712 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) Sheet http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) Details 31 false false R32.htm 9954713 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) Sheet http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail Inventory - Schedule of Inventory, Current (Detail) Details 32 false false R33.htm 9954714 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Details) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails Right of Use Assets and Lease Liabilities - Additional Information (Details) Details 33 false false R34.htm 9954715 - Disclosure - Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) Details 34 false false R35.htm 9954716 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) Details 35 false false R36.htm 9954717 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 36 false false R37.htm 9954718 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) Details 37 false false R38.htm 9954719 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail Share-Based Compensation - Stock Options Activity (Detail) Details 38 false false R39.htm 9954720 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) Details 39 false false R40.htm 9954721 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Details 40 false false R41.htm 9954722 - Disclosure - Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) Sheet http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) Details 41 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: ecd:TrdArrDuration - itci-20230630.htm 4 itci-20230630.htm itci-20230630.xsd itci-20230630_cal.xml itci-20230630_def.xml itci-20230630_lab.xml itci-20230630_pre.xml itci-20230630xex311.htm itci-20230630xex312.htm itci-20230630xex32.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 58 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "itci-20230630.htm": { "axisCustom": 0, "axisStandard": 19, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 502, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 17 }, "contextCount": 171, "dts": { "calculationLink": { "local": [ "itci-20230630_cal.xml" ] }, "definitionLink": { "local": [ "itci-20230630_def.xml" ] }, "inline": { "local": [ "itci-20230630.htm" ] }, "labelLink": { "local": [ "itci-20230630_lab.xml" ] }, "presentationLink": { "local": [ "itci-20230630_pre.xml" ] }, "schema": { "local": [ "itci-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 411, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 5, "http://xbrl.sec.gov/ecd/2023": 2, "total": 7 }, "keyCustom": 13, "keyStandard": 191, "memberCustom": 10, "memberStandard": 27, "nsprefix": "itci", "nsuri": "http://www.intracellulartherapies.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.intracellulartherapies.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Investment Securities", "menuCat": "Notes", "order": "11", "role": "http://www.intracellulartherapies.com/role/InvestmentSecurities", "shortName": "Investment Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "12", "role": "http://www.intracellulartherapies.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Inventory", "menuCat": "Notes", "order": "13", "role": "http://www.intracellulartherapies.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "itci:RightOfUseAssetsAndLeaseLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Right of Use Assets and Lease Liabilities", "menuCat": "Notes", "order": "14", "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities", "shortName": "Right of Use Assets and Lease Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "itci:RightOfUseAssetsAndLeaseLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "15", "role": "http://www.intracellulartherapies.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Share-Based Compensation", "menuCat": "Notes", "order": "16", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Loss Per Share", "menuCat": "Notes", "order": "17", "role": "http://www.intracellulartherapies.com/role/LossPerShare", "shortName": "Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-13", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "menuCat": "Notes", "order": "18", "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "shortName": "Pay vs Performance Disclosure", "subGroupType": "", "uniqueAnchor": null }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-13", "decimals": null, "first": true, "lang": "en-US", "name": "ecd:NonRule10b51ArrAdoptedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995445 - Disclosure - Insider Trading Arrangements", "menuCat": "Notes", "order": "19", "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "shortName": "Insider Trading Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-13", "decimals": null, "first": true, "lang": "en-US", "name": "ecd:NonRule10b51ArrAdoptedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954701 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "20", "role": "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954702 - Disclosure - Investment Securities (Tables)", "menuCat": "Tables", "order": "21", "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables", "shortName": "Investment Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954703 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.intracellulartherapies.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954704 - Disclosure - Inventory (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.intracellulartherapies.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954705 - Disclosure - Right of Use Assets and Lease Liabilities (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables", "shortName": "Right of Use Assets and Lease Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954706 - Disclosure - Share-Based Compensation (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954707 - Disclosure - Loss Per Share - (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.intracellulartherapies.com/role/LossPerShareTables", "shortName": "Loss Per Share - (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954708 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "menuCat": "Details", "order": "27", "role": "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954709 - Disclosure - Investment Securities - Summary of Investment Securities (Detail)", "menuCat": "Details", "order": "28", "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail", "shortName": "Investment Securities - Summary of Investment Securities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954710 - Disclosure - Investment Securities - Additional Information (Detail)", "menuCat": "Details", "order": "29", "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "shortName": "Investment Securities - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954711 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "menuCat": "Details", "order": "30", "role": "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "shortName": "Fair Value Measurements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-104", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954712 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail)", "menuCat": "Details", "order": "31", "role": "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "shortName": "Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-104", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954713 - Disclosure - Inventory - Schedule of Inventory, Current (Detail)", "menuCat": "Details", "order": "32", "role": "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail", "shortName": "Inventory - Schedule of Inventory, Current (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-137", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954714 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Details)", "menuCat": "Details", "order": "33", "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails", "shortName": "Right of Use Assets and Lease Liabilities - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-137", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954715 - Disclosure - Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)", "menuCat": "Details", "order": "34", "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail", "shortName": "Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954716 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)", "menuCat": "Details", "order": "35", "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail", "shortName": "Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-144", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954717 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "menuCat": "Details", "order": "36", "role": "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-145", "decimals": "-5", "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954718 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)", "menuCat": "Details", "order": "37", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail", "shortName": "Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-146", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-4", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954719 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail)", "menuCat": "Details", "order": "38", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "shortName": "Share-Based Compensation - Stock Options Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-153", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954720 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)", "menuCat": "Details", "order": "39", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "shortName": "Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-155", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-13", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-13", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-157", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954721 - Disclosure - Share-Based Compensation - Additional Information (Detail)", "menuCat": "Details", "order": "40", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "shortName": "Share-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-157", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-158", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954722 - Disclosure - Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)", "menuCat": "Details", "order": "41", "role": "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail", "shortName": "Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-158", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-13", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "menuCat": "Statements", "order": "5", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-13", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-20", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "menuCat": "Statements", "order": "6", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-21", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)", "menuCat": "Statements", "order": "8", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-39", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Organization", "menuCat": "Notes", "order": "9", "role": "http://www.intracellulartherapies.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "itci-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 43, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "ecd_Additional402vDisclosureTextBlock": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "localname": "Additional402vDisclosureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToCompAmt": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "localname": "AdjToCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AdjToCompAxis": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "localname": "AdjToCompAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "localname": "AdjToNonPeoNeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToPeoCompFnTextBlock": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "localname": "AdjToPeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AggtErrCompAmt": { "auth_ref": [ "r538", "r549", "r559", "r584" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "localname": "AggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "auth_ref": [ "r541", "r552", "r562", "r587" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "localname": "AggtErrCompNotYetDeterminedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AllAdjToCompMember": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "localname": "AllAdjToCompMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllExecutiveCategoriesMember": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "localname": "AllExecutiveCategoriesMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllIndividualsMember": { "auth_ref": [ "r545", "r553", "r563", "r580", "r588", "r592", "r600" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "localname": "AllIndividualsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllTradingArrangementsMember": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "localname": "AllTradingArrangementsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "domainItemType" }, "ecd_AwardExrcPrice": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "localname": "AwardExrcPrice", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "perShareItemType" }, "ecd_AwardGrantDateFairValue": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "localname": "AwardGrantDateFairValue", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AwardTmgDiscLineItems": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "localname": "AwardTmgDiscLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMethodTextBlock": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "localname": "AwardTmgMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMnpiCnsdrdFlag": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "localname": "AwardTmgMnpiCnsdrdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardTmgMnpiDiscTextBlock": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "localname": "AwardTmgMnpiDiscTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgPredtrmndFlag": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "localname": "AwardTmgPredtrmndFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardUndrlygSecuritiesAmt": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "localname": "AwardUndrlygSecuritiesAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_AwardsCloseToMnpiDiscIndName": { "auth_ref": [ "r593" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "localname": "AwardsCloseToMnpiDiscIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTable": { "auth_ref": [ "r592" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "localname": "AwardsCloseToMnpiDiscTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "auth_ref": [ "r592" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "localname": "AwardsCloseToMnpiDiscTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ChangedPeerGroupFnTextBlock": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "localname": "ChangedPeerGroupFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CoSelectedMeasureAmt": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "localname": "CoSelectedMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_CoSelectedMeasureName": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "localname": "CoSelectedMeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "localname": "CompActuallyPaidVsNetIncomeTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompAnalysisTextBlock": { "auth_ref": [ "r538", "r549", "r559", "r584" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "localname": "ErrCompAnalysisTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompRecoveryTable": { "auth_ref": [ "r535", "r546", "r556", "r581" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "localname": "ErrCompRecoveryTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ExecutiveCategoryAxis": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "localname": "ExecutiveCategoryAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "auth_ref": [ "r542", "r553", "r563", "r588" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "auth_ref": [ "r542", "r553", "r563", "r588" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "auth_ref": [ "r542", "r553", "r563", "r588" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "auth_ref": [ "r542", "r553", "r563", "r588" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ForgoneRecoveryIndName": { "auth_ref": [ "r542", "r553", "r563", "r588" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "ForgoneRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_IndividualAxis": { "auth_ref": [ "r545", "r553", "r563", "r580", "r588", "r592", "r600" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "localname": "IndividualAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_InsiderTradingArrLineItems": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "localname": "InsiderTradingArrLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTradingPoliciesProcLineItems": { "auth_ref": [ "r534", "r604" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "localname": "InsiderTradingPoliciesProcLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "auth_ref": [ "r534", "r604" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "localname": "InsiderTrdPoliciesProcAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "booleanItemType" }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "auth_ref": [ "r534", "r604" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "textBlockItemType" }, "ecd_MeasureAxis": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "localname": "MeasureAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_MeasureName": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "localname": "MeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_MnpiDiscTimedForCompValFlag": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "localname": "MnpiDiscTimedForCompValFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_MtrlTermsOfTrdArrTextBlock": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "localname": "MtrlTermsOfTrdArrTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "textBlockItemType" }, "ecd_NamedExecutiveOfficersFnTextBlock": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "localname": "NamedExecutiveOfficersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonGaapMeasureDescriptionTextBlock": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "localname": "NonGaapMeasureDescriptionTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonNeosMember": { "auth_ref": [ "r542", "r553", "r563", "r580", "r588" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "localname": "NonNeosMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoAvgTotalCompAmt": { "auth_ref": [ "r569" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "localname": "NonPeoNeoAvgTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoMember": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "localname": "NonPeoNeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonRule10b51ArrAdoptedFlag": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "localname": "NonRule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_NonRule10b51ArrTrmntdFlag": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "localname": "NonRule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_OtherPerfMeasureAmt": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "localname": "OtherPerfMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_OutstandingAggtErrCompAmt": { "auth_ref": [ "r540", "r551", "r561", "r586" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "localname": "OutstandingAggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryCompAmt": { "auth_ref": [ "r543", "r554", "r564", "r589" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "localname": "OutstandingRecoveryCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryIndName": { "auth_ref": [ "r543", "r554", "r564", "r589" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "OutstandingRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PayVsPerformanceDisclosureLineItems": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "localname": "PayVsPerformanceDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_PeerGroupIssuersFnTextBlock": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "localname": "PeerGroupIssuersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_PeerGroupTotalShareholderRtnAmt": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "localname": "PeerGroupTotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoActuallyPaidCompAmt": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "localname": "PeoActuallyPaidCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoMember": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "localname": "PeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_PeoName": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "localname": "PeoName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_PeoTotalCompAmt": { "auth_ref": [ "r569" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "localname": "PeoTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PvpTable": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "localname": "PvpTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PvpTableTextBlock": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "localname": "PvpTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "auth_ref": [ "r535", "r546", "r556", "r581" ], "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "localname": "RecoveryOfErrCompDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_RestatementDateAxis": { "auth_ref": [ "r536", "r547", "r557", "r582" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "localname": "RestatementDateAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_RestatementDeterminationDate": { "auth_ref": [ "r537", "r548", "r558", "r583" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "localname": "RestatementDeterminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "dateItemType" }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "auth_ref": [ "r544", "r555", "r565", "r590" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "localname": "RestatementDoesNotRequireRecoveryTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_Rule10b51ArrAdoptedFlag": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "localname": "Rule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_Rule10b51ArrTrmntdFlag": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "localname": "Rule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "auth_ref": [ "r539", "r550", "r560", "r585" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "localname": "StkPrcOrTsrEstimationMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TabularListTableTextBlock": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "localname": "TabularListTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TotalShareholderRtnAmt": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "localname": "TotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TradingArrAxis": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "localname": "TradingArrAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TradingArrByIndTable": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "localname": "TradingArrByIndTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrAdoptionDate": { "auth_ref": [ "r601" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "localname": "TrdArrAdoptionDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrDuration": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "localname": "TrdArrDuration", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "durationItemType" }, "ecd_TrdArrIndName": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "localname": "TrdArrIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrIndTitle": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "localname": "TrdArrIndTitle", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrSecuritiesAggAvailAmt": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "localname": "TrdArrSecuritiesAggAvailAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "sharesItemType" }, "ecd_TrdArrTerminationDate": { "auth_ref": [ "r601" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "localname": "TrdArrTerminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_UndrlygSecurityMktPriceChngPct": { "auth_ref": [ "r597" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "localname": "UndrlygSecurityMktPriceChngPct", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "pureItemType" }, "itci_AccruedCustomerProgramsCurrent": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued customer programs current.", "label": "Accrued Customer Programs Current", "terseLabel": "Accrued customer programs" } } }, "localname": "AccruedCustomerProgramsCurrent", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "itci_BristolMyersSquibbCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bristol Myers Squibb company.", "label": "Bristol Myers Squibb Company [Member]", "terseLabel": "Bristol-Myers Squibb Company" } } }, "localname": "BristolMyersSquibbCompanyMember", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_CollaborativeAgreementUpfrontPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Agreement Upfront Payments", "label": "Collaborative Agreement Upfront Payments", "terseLabel": "Company made an upfront payment" } } }, "localname": "CollaborativeAgreementUpfrontPayments", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_CollaborativeArrangementAmountPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement amount payable.", "label": "Collaborative Arrangement Amount Payable", "terseLabel": "Obliged to make milestone payments" } } }, "localname": "CollaborativeArrangementAmountPayable", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_CollaborativeArrangementLicenseExpirationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement license expiration description.", "label": "Collaborative Arrangement License Expiration Term", "terseLabel": "License expiration period" } } }, "localname": "CollaborativeArrangementLicenseExpirationTerm", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "itci_CostOfProductSales": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of product sales.", "label": "Cost Of Product Sales", "terseLabel": "Cost of product sales" } } }, "localname": "CostOfProductSales", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "itci_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer one.", "label": "Customer One [Member]", "terseLabel": "Customer One" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer three.", "label": "Customer Three [Member]", "terseLabel": "Customer Three" } } }, "localname": "CustomerThreeMember", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer two.", "label": "Customer Two [Member]", "terseLabel": "Customer Two" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_DebtSecuritiesAvailableForSaleUnrealizedLossesPercentageOfFairValueOfInvestments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available For Sale, Unrealized Losses, Percentage Of Fair Value Of Investments", "label": "Debt Securities, Available For Sale, Unrealized Losses, Percentage Of Fair Value Of Investments", "negatedTerseLabel": "Percentage of fair value instruments" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossesPercentageOfFairValueOfInvestments", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "itci_FDICCertificatesOfDepositMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FDIC certificates of deposit.", "label": "FDIC Certificates Of Deposit [Member]", "terseLabel": "FDIC Certificates of Deposit" } } }, "localname": "FDICCertificatesOfDepositMember", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "itci_IncreaseDecreaseInAccruedCustomerPrograms": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued customer programs.", "label": "Increase Decrease In Accrued Customer Programs", "negatedLabel": "Accrued customer programs" } } }, "localname": "IncreaseDecreaseInAccruedCustomerPrograms", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "itci_InventoriableCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "InventoriableCostsMember.", "label": "Inventoriable Costs [Member]", "terseLabel": "Inventoriable costs" } } }, "localname": "InventoriableCostsMember", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after Year four.", "label": "Lessee Operating Lease Liability Payments Due after Year Four", "verboseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "xbrltype": "monetaryItemType" }, "itci_MichaelIHalsteadMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Michael I. Halstead", "label": "Michael I. Halstead [Member]" } } }, "localname": "MichaelIHalsteadMember", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "domainItemType" }, "itci_OtherInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other information.", "label": "Other Information [Abstract]", "verboseLabel": "Other information" } } }, "localname": "OtherInformationAbstract", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "stringItemType" }, "itci_PossibleMilestonePaymentsRemaining": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment of milestone amount.", "label": "Possible Milestone Payments Remaining", "terseLabel": "Payment of milestone amount" } } }, "localname": "PossibleMilestonePaymentsRemaining", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_RightOfUseAssetsAndLeaseLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right of use assets and lease liabilities.", "label": "Right Of Use Assets And Lease Liabilities [Text Block]", "terseLabel": "Right of Use Assets and Lease Liabilities" } } }, "localname": "RightOfUseAssetsAndLeaseLiabilitiesTextBlock", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities" ], "xbrltype": "textBlockItemType" }, "itci_RoyaltyPaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Payment Percentage", "label": "Royalty Payment Percentage", "terseLabel": "Royalty payment, percentage (as a percent)" } } }, "localname": "RoyaltyPaymentPercentage", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Quantitative Information About Operating Leases", "label": "Schedule of Quantitative Information About Operating Leases [Table Text Block]", "terseLabel": "Schedule of Quantitative Information About Operating Leases" } } }, "localname": "ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsActivityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward]", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsActivityRollForward", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "xbrltype": "stringItemType" }, "itci_SharonMatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharon Mates", "label": "Sharon Mates [Member]" } } }, "localname": "SharonMatesMember", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "domainItemType" }, "itci_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_SignificantAccountingPoliciesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Policy Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesPolicyTextBlock", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "itci_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_ThreeMajorWholesalersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Major Wholesalers", "label": "Three Major Wholesalers [Member]", "terseLabel": "Three Major Wholesalers" } } }, "localname": "ThreeMajorWholesalersMember", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_TimeBasedRestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Time based restricted stock units.", "label": "Time Based Restricted Stock Units R S U [Member]", "terseLabel": "Time Based Restricted Stock Units" } } }, "localname": "TimeBasedRestrictedStockUnitsRSUMember", "nsuri": "http://www.intracellulartherapies.com/20230630", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r121", "r122", "r231", "r234", "r332", "r494", "r496" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r164", "r507", "r646", "r666", "r667" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r217", "r218", "r219", "r220", "r246", "r363", "r392", "r414", "r415", "r466", "r468", "r470", "r471", "r476", "r486", "r487", "r501", "r505", "r511", "r518", "r645", "r658", "r659", "r660", "r661", "r662", "r663" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r217", "r218", "r219", "r220", "r246", "r363", "r392", "r414", "r415", "r466", "r468", "r470", "r471", "r476", "r486", "r487", "r501", "r505", "r511", "r518", "r645", "r658", "r659", "r660", "r661", "r662", "r663" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r164", "r507", "r646", "r666", "r667" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r162", "r364", "r386", "r387", "r388", "r389", "r390", "r391", "r488", "r506", "r517", "r609", "r641", "r642", "r646", "r666" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r162", "r364", "r386", "r387", "r388", "r389", "r390", "r391", "r488", "r506", "r517", "r609", "r641", "r642", "r646", "r666" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r217", "r218", "r219", "r220", "r239", "r246", "r274", "r275", "r276", "r339", "r363", "r392", "r414", "r415", "r466", "r468", "r470", "r471", "r476", "r486", "r487", "r501", "r505", "r511", "r518", "r521", "r639", "r645", "r659", "r660", "r661", "r662", "r663" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r217", "r218", "r219", "r220", "r239", "r246", "r274", "r275", "r276", "r339", "r363", "r392", "r414", "r415", "r466", "r468", "r470", "r471", "r476", "r486", "r487", "r501", "r505", "r511", "r518", "r521", "r639", "r645", "r659", "r660", "r661", "r662", "r663" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r485", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r485", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r121", "r122", "r231", "r234", "r332", "r495", "r496" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "stpr_NY": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK", "terseLabel": "NEW YORK" } } }, "localname": "NY", "nsuri": "http://xbrl.sec.gov/stpr/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r18", "r516" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r165", "r166" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r67" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premiums and accretion of discounts on investment securities, net" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued employee benefits" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r23", "r24", "r58", "r102", "r374", "r397", "r398" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r2", "r10", "r24", "r297", "r300", "r331", "r393", "r394", "r621", "r622", "r623", "r627", "r628", "r629" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "verboseLabel": "Accumulated Comprehensive (Loss) Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r50" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r281", "r282", "r283", "r406", "r627", "r628", "r629", "r652", "r670" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r38", "r39", "r249" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Number of anti-dilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r79", "r101", "r120", "r149", "r156", "r160", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r290", "r294", "r313", "r371", "r436", "r516", "r529", "r643", "r644", "r656" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r96", "r104", "r120", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r290", "r294", "r313", "r516", "r643", "r644", "r656" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets measured using quoted prices", "verboseLabel": "Available-for-sale investment securities" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r172" ], "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r173" ], "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized (Losses)" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r170", "r206", "r365", "r632" ], "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r167", "r206" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Investment securities, available-for-sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r99", "r167", "r206" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-Sale, Noncurrent", "terseLabel": "Investment securities, available for sale, noncurrent" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r87", "r372", "r407", "r431", "r516", "r529", "r619" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash paid" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r27", "r98", "r489" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r27", "r65", "r118" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r65" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositAtCarryingValue": { "auth_ref": [ "r619" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Certificates of Deposit, at Carrying Value", "terseLabel": "Certificates of deposits" } } }, "localname": "CertificatesOfDepositAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r8", "r523", "r524", "r525", "r526" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of Deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Commercial Paper, at Carrying Value", "verboseLabel": "Commercial paper value listed as cash equivalent" } } }, "localname": "CommercialPaperAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r73", "r523", "r524", "r525", "r526" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r72", "r215", "r216", "r484", "r640" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r519", "r520", "r521", "r523", "r524", "r525", "r526", "r627", "r628", "r652", "r669", "r670" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r49", "r423" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r11", "r49", "r423", "r442", "r670", "r671" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r49", "r373", "r516" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.0001 par value: 175,000,000 shares authorized at June\u00a030, 2023 and December\u00a031, 2022; 96,083,387 and 94,829,794 shares issued and outstanding at June\u00a030, 2023 and December\u00a031, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r25", "r107", "r109", "r114", "r367", "r383" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r29", "r31", "r42", "r43", "r164", "r483" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r29", "r31", "r42", "r43", "r164", "r399", "r483" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r29", "r31", "r42", "r43", "r164", "r483", "r607" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r44", "r90" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r29", "r31", "r42", "r43", "r164" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk (as a percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r29", "r31", "r42", "r43", "r164", "r483" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r508", "r510", "r668" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Notes/Bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r30", "r164" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": { "auth_ref": [ "r633" ], "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss", "totalLabel": "Amortized Cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r85", "r209", "r502" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Aggregate fair value of investments with unrealized losses" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r85", "r209", "r502" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Continuous unrealized losses, value remaining" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-Sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r84", "r208", "r502" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "terseLabel": "Aggregate related fair value of investments with unrealized losses" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r6", "r35" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r247", "r251", "r278", "r279", "r280", "r512" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r115", "r128", "r129", "r130", "r131", "r132", "r137", "r139", "r141", "r142", "r143", "r147", "r304", "r305", "r368", "r384", "r498" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r115", "r128", "r129", "r130", "r131", "r132", "r139", "r141", "r142", "r143", "r147", "r304", "r305", "r368", "r384", "r498" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r136", "r144", "r145", "r146" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r651" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation costs related to unvested RSUs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Share-Based Payment Arrangement, Option [Member]", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r11", "r94", "r110", "r111", "r112", "r123", "r124", "r125", "r127", "r133", "r135", "r148", "r199", "r200", "r236", "r281", "r282", "r283", "r286", "r287", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r314", "r316", "r317", "r318", "r319", "r320", "r331", "r393", "r394", "r395", "r406", "r462" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r307", "r308", "r311" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r307", "r308", "r311" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r40", "r78" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities" } } }, "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r40", "r41" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r232", "r240", "r241", "r242", "r243", "r244", "r245", "r308", "r336", "r337", "r338", "r503", "r504", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r307", "r308", "r309", "r310", "r312" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r232", "r240", "r245", "r308", "r336", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r232", "r240", "r245", "r308", "r337", "r503", "r504", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r232", "r240", "r241", "r242", "r243", "r244", "r245", "r308", "r338", "r503", "r504", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r232", "r240", "r241", "r242", "r243", "r244", "r245", "r336", "r337", "r338", "r503", "r504", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r306", "r312" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r201", "r202", "r203", "r204", "r205", "r207", "r210", "r211", "r233", "r235", "r302", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r382", "r502", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r634", "r635", "r636", "r637" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r61", "r446" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r647" ], "lang": { "en-us": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Grant [Member]", "terseLabel": "Grant revenue" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "us-gaap_GuaranteeObligationsCurrentCarryingValue": { "auth_ref": [ "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.", "label": "Guarantor Obligations, Current Carrying Value", "terseLabel": "Guarantor obligations, value" } } }, "localname": "GuaranteeObligationsCurrentCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r59", "r82", "r149", "r155", "r159", "r161", "r369", "r378", "r500" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r213", "r214", "r447" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r214", "r447" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r86", "r93", "r134", "r135", "r153", "r285", "r288", "r385" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r5" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r5" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r624" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r5" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued employee benefits" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r5" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r608", "r624" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities, net" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r5" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r70", "r491" ], "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r103", "r490", "r516" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r70", "r493" ], "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r70", "r492" ], "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r62", "r152" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r610", "r611", "r631" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment.", "label": "Investment [Text Block]", "terseLabel": "Investment Securities" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r409", "r410", "r411", "r412", "r413", "r465", "r467", "r469", "r472", "r473", "r474", "r475", "r477", "r478", "r479", "r480", "r481", "r521" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r409", "r410", "r411", "r412", "r413", "r465", "r467", "r469", "r472", "r473", "r474", "r475", "r477", "r478", "r479", "r480", "r481", "r521" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r6" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Stock issued for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r323", "r515" ], "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "verboseLabel": "Lease cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r655" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule Of Maturity Analysis Under Lease Agreements" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r330" ], "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "Year ending December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "verboseLabel": "Year ending December 31, 2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "Year ending December 31, 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "Year ending December 31, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r655" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "verboseLabel": "Six months ending December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r330" ], "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of long term lease" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r19", "r120", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r291", "r294", "r295", "r313", "r422", "r499", "r529", "r643", "r656", "r657" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r54", "r81", "r376", "r516", "r626", "r638", "r653" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r21", "r97", "r120", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r291", "r294", "r295", "r313", "r516", "r643", "r656", "r657" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities measured using quoted prices" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Carrying value of cash held in money market funds" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r648" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r117" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r117" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r65", "r66", "r67" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r60", "r67", "r83", "r95", "r105", "r108", "r112", "r120", "r126", "r128", "r129", "r130", "r131", "r134", "r135", "r140", "r149", "r155", "r159", "r161", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r305", "r313", "r380", "r444", "r460", "r461", "r500", "r527", "r643" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r149", "r155", "r159", "r161", "r500" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r324", "r515" ], "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "verboseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r322" ], "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r322" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedTerseLabel": "Less: Current portion", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r322" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current", "verboseLabel": "Operating lease liabilities, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r321" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right of use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r329", "r515" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Weighted average discount rate (as a percent)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r328", "r515" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r46", "r76", "r400", "r401" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r100" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r4", "r9", "r77" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized gain (loss) on investment securities" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r11", "r16", "r106", "r109", "r113", "r314", "r315", "r320", "r366", "r381", "r621", "r622" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "verboseLabel": "Other comprehensive gain (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r63" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r64" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r620" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r3" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds of public offering, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r26" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r3", "r15" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product", "verboseLabel": "Product sales, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r95", "r105", "r108", "r116", "r120", "r126", "r134", "r135", "r149", "r155", "r159", "r161", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r289", "r292", "r293", "r305", "r313", "r369", "r379", "r405", "r444", "r460", "r461", "r500", "r513", "r514", "r528", "r623", "r643" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r370", "r377", "r516" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "auth_ref": [ "r47", "r80" ], "lang": { "en-us": { "role": { "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.", "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "terseLabel": "Purchase Commitment, Excluding Long-Term Commitment [Axis]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "auth_ref": [ "r47", "r80" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.", "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "terseLabel": "Purchase Commitment, Excluding Long-Term Commitment [Domain]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentMember": { "auth_ref": [ "r47", "r80" ], "lang": { "en-us": { "role": { "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments.", "label": "Purchase Commitment [Member]", "terseLabel": "Purchase Commitment" } } }, "localname": "PurchaseCommitmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r45", "r284", "r664" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r619", "r625" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r51", "r74", "r375", "r396", "r398", "r404", "r424", "r516" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r94", "r123", "r124", "r125", "r127", "r133", "r135", "r199", "r200", "r281", "r282", "r283", "r286", "r287", "r296", "r298", "r299", "r301", "r303", "r393", "r395", "r406", "r670" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r150", "r151", "r154", "r157", "r158", "r162", "r163", "r164", "r237", "r238", "r364" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "verboseLabel": "Total revenues, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]", "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]" } } }, "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]", "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Table]" } } }, "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r327", "r515" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "verboseLabel": "Right of use assets under operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r164", "r606" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-Sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of Investment Securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r17", "r55", "r56", "r57" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory, Current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r248", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r13", "r14", "r36" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Information Regarding RSU Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r5" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation", "verboseLabel": "Total share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Time based RSU's cancelled, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Time based RSU's cancelled, Weighted-Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Time based RSU's granted, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Time based RSU's granted, Weighted-Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r263", "r264" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at end of year, Number of Shares (in shares)", "periodStartLabel": "Outstanding at beginning of year, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r263", "r264" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding at end of year, Weighted-Average Grant Date Fair Value (in dollars per share)", "periodStartLabel": "Outstanding at beginning of year, Weighted-Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Restricted stock outstanding, Weighted-Average Contractual Life (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Time based RSU's vested, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Time based RSU's vested, Weighted-Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r248", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of period, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of period, Weighted-Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r649" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Options canceled or expired, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Options granted, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period, Number of Shares (in shares)", "periodStartLabel": "Outstanding at beginning of period, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period, Weighted-Average Exercise Price (in dollars per share)", "periodStartLabel": "Outstanding at beginning of period, Weighted-Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested or expected to vest at end of period, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested or expected to vest at end of period, Weighted-Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding at end of period, Weighted-Average Contractual Life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r325", "r515" ], "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r68", "r119" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r11", "r22", "r94", "r110", "r111", "r112", "r123", "r124", "r125", "r127", "r133", "r135", "r148", "r199", "r200", "r236", "r281", "r282", "r283", "r286", "r287", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r314", "r316", "r317", "r318", "r319", "r320", "r331", "r393", "r394", "r395", "r406", "r462" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r123", "r124", "r125", "r148", "r364", "r402", "r408", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r426", "r427", "r428", "r429", "r430", "r432", "r433", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r443", "r445", "r446", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r462", "r522" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r123", "r124", "r125", "r148", "r364", "r402", "r408", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r426", "r427", "r428", "r429", "r430", "r432", "r433", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r443", "r445", "r446", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r462", "r522" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockAppreciationRightsSARSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.", "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "localname": "StockAppreciationRightsSARSMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Stock issued for services (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r11", "r48", "r49", "r74", "r403", "r462", "r482" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Common shares issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r11", "r48", "r49", "r74" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Exercise of stock options and issuances of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r11", "r48", "r49", "r74", "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised, Number of Shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Stock issued for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r48", "r49", "r74", "r406", "r462", "r482", "r528" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Common shares issued" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r11", "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Exercise of stock options and issuances of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r49", "r52", "r53", "r69", "r425", "r442", "r463", "r464", "r516", "r529", "r626", "r638", "r653", "r670" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r233", "r235", "r302", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r382", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r634", "r635", "r636", "r637" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r497", "r508", "r665" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Government Agency Securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt securities issued by a United States government agency such as Government National Mortgage Association (Ginnie Mae), Federal Home Loan Mortgage Corporation (Freddie Mac), and Federal National Mortgage Association (Fannie Mae), which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "US Government Agencies Securities, at Carrying Value", "terseLabel": "Carrying value of cash held in commercial paper, government securities" } } }, "localname": "USGovernmentAgenciesSecuritiesAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r32", "r33", "r34", "r88", "r89", "r91", "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r326", "r515" ], "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]", "terseLabel": "Vehicle Lease" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r138", "r143" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in share)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r137", "r143" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted average number of common shares:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r531": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r532": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r533": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r534": { "Name": "Form 20-F", "Paragraph": "a", "Publisher": "SEC", "Section": "16", "Subsection": "J", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r535": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r536": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r537": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "A", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r538": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "B", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r539": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "C", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "D", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r541": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "E", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r542": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r543": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "iii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r544": { "Name": "Form 20-F", "Paragraph": "2", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r545": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r546": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r547": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r548": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r549": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r551": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r552": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r553": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r554": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r555": { "Name": "Form 40-F", "Paragraph": "b", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r556": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r557": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r558": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r559": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r561": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r562": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r563": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r564": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r565": { "Name": "Form N-CSR", "Paragraph": "b", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r566": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r567": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r568": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r569": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r571": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r572": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "vi", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r573": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "3", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r574": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "4", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r575": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r576": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r577": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r578": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r579": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r581": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r582": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r583": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r584": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "B", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r585": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r586": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r587": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r588": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r589": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r591": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r592": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r593": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r594": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r595": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r596": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r597": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "F", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r598": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r599": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "A", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r601": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "B", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r602": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "C", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r603": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "D", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r604": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r605": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "https://asc.fasb.org//321/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "https://asc.fasb.org//325/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 59 0001628280-23-027013-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-027013-xbrl.zip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end